var title_f19_45_20176="Melanoma pathology worksheet";
var content_f19_45_20176=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ONC%2F65104&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ONC%2F65104&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 571px\">",
"   <div class=\"ttl\">",
"    Massachusetts General Hospital malignant melanoma worksheet",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 551px; height: 701px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Liu ,V, Mihm, MC. Pathology of malignant melanoma. Surg Clin North Am 2003; 83:31. Copyright &copy; 2003 Elsevier Science.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f19_45_20176=[""].join("\n");
var outline_f19_45_20176=null;
var title_f19_45_20177="Endomicroscopic image of neoplasia in Barretts esophagus";
var content_f19_45_20177=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F64674&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F64674&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Endomicroscopic image of neoplasia in Barrett's esophagus",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 286px; height: 571px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Endomicroscopic image of neoplasia arising from Barrett's esophagus (Panel A) and benign Barrett's metaplasia (Panel B). Cancerous tissue shows a loss of epithelial structures. The epithelium becomes dark and the vasculature is irregular with leakage of fluorescein. Benign mucosa is characterized by a more tubular shaped pattern with a regular and constant width of the epithelial layer. In addition, goblet cells (dark spots within the epithelial layer) can be clearly identified.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Alexander Meining, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f19_45_20177=[""].join("\n");
var outline_f19_45_20177=null;
var title_f19_45_20178="How doctors check breast tissue in men PI";
var content_f19_45_20178=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PI%2F65845&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PI%2F65845&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 563px\">",
"   <div class=\"ttl\">",
"    How doctors check breast tissue in men",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 543px; height: 539px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    To check a man's breast, the doctor or nurse will bring his or her fingers together around the nipple (as shown). If the tissue is breast tissue and not fat, the doctor or nurse should feel a rubbery or firm circle of tissue centered under the nipple. (When men develop breast tissue, it is called \"gynecomastia.\") If the tissue is fat, the doctor or nurse will not feel any firm bit of tissue. The whole breast will feel soft.",
"    <br>",
"     The doctor or nurse will also check if the firm tissue is at the center of the breast or off to the side. If there is firm tissue that is not centered, it could be cancer.",
"     <div class=\"footnotes\">",
"     </div>",
"     <div class=\"reference\">",
"     </div>",
"    </br>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f19_45_20178=[""].join("\n");
var outline_f19_45_20178=null;
var title_f19_45_20179="Secretin: Pediatric drug information";
var content_f19_45_20179=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Secretin: Pediatric drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_general\" href=\"UTD.htm?27/49/28435?source=see_link\">",
"    see \"Secretin: Drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?17/24/17795?source=see_link\">",
"    see \"Secretin: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F220255\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      ChiRhoStim&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F1062048\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Therapeutic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Diagnostic Agent, Gastrinoma (Zollinger-Ellison Syndrome)",
"      </span>",
"     </li>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Diagnostic Agent, Pancreatic Exocrine Insufficiency",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block dos drugH1Div\" id=\"F1062041\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Usual",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_general\" href=\"UTD.htm?27/49/28435?source=see_link\">",
"      see \"Secretin: Drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Children and Adults: I.V.:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Diagnostic agent for pancreatic function: 0.2 mcg/kg as single dose",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Diagnostic agent for gastrinoma (Zollinger-Ellison): 0.4 mcg/kg as single dose",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Facilitation of ERCP visualization: 0.2 mcg/kg as a single dose",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F220238\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, powder for reconstitution [human derived]:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     ChiRhoStim&reg;: 16 mcg",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F220223\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F1062052\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Parenteral: Reconstitute with 8 mL of NS resulting in a 2 mcg/mL solution; shake vigorously to ensure dissolution; use immediately by direct I.V. injection slowly over 1 minute",
"    </p>",
"   </div>",
"   <div class=\"block sta drugH1Div\" id=\"F1062044\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Stability",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Store in freezer (-20&deg;C); SecreFlo&trade; should be used immediately after reconstitution; human secretin is also stable for 1 year refrigerated and 6 months at room temperature",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F1062051\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Diagnosis of gastrinoma (Zollinger-Ellison syndrome) and diagnosis of pancreatic exocrine dysfunction (chronic pancreatitis); facilitation of endoscopic retrograde cholangiopancreatography (ERCP) visualization",
"    </p>",
"   </div>",
"   <div class=\"block arm drugH1Div\" id=\"F220274\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cardiovascular: Flushing",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gastrointestinal: Abdominal discomfort/pain, nausea, vomiting",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Miscellaneous: Bleeding (sphincterectomy)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Rare but important or life-threatening: Abdominal cramps, anxiety, bloating, bradycardia (mild), diaphoresis, diarrhea, dyspepsia, faintness, fatigue, fever, headache, heart rate increased, hypotension, leukocytoplastic vasculitis, lightheadedness, numbness/tingling in the extremities, oral secretions increased, oxygen saturation decreased, pallor, pancreatitis (mild), rash (abdominal), respiratory distress (transient), sedation, seizure, warm sensation (abdomen/face)",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F1062056\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to secretin or any component; do not give to patients with acute pancreatitis until attack has subsided",
"    </p>",
"   </div>",
"   <div class=\"block pre drugH1Div\" id=\"F1062040\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Precautions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Administer an I.V. test dose of 0.2 mcg (0.1 mL) particularly in patients with a history of hypersensitivity, allergy or asthma; use with caution in patients who are highly nervous or have an excessive gag reflex; patients receiving anticholinergics, patients who have had a vagotomy, or patients with inflammatory bowel disease may have a reduced response to secretin; patients with alcoholic or other liver diseases may have an increased response to secretin",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13300032\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F220231\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Anticholinergic Agents: May diminish the therapeutic effect of Secretin.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F220233\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F220244\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Reproduction studies have not been conducted.",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F1062047\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Peak bicarbonate concentration of duodenal fluid aspirate (chronic pancreatitis); serum gastrin (gastrinoma)",
"    </p>",
"   </div>",
"   <div class=\"block rer drugH1Div\" id=\"F1062050\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Reference Range",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Peak gastric bicarbonate concentration:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Normal: 94-134 mEq/L",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Chronic pancreatitis: &lt;80 mEq/L",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Severe pancreatitis: &lt;50 mEq/L",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Serum gastrin:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Normal: &le;110 pg/mL",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastrinoma: &gt;110 pg/mL",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F1062039\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Secretin is a naturally-occurring hormone secreted by cells in the duodenal and upper jejunal mucosa which increases the volume and bicarbonate content of pancreatic juice; when used as a diagnostic agent, synthetic porcine secretin stimulates an increase in gastrin release in patients with Zollinger-Ellison syndrome when compared with normal patients; gastrin bicarbonate concentration is reduced in patients with chronic pancreatitis when compared with a normal patient's response to secretin",
"    </p>",
"   </div>",
"   <div class=\"block phd drugH1Div\" id=\"F1062054\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Maximum output of pancreatic secretions: Within 30 minutes",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Duration: At least 2 hours",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F1062055\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacokinetics (Adult data unless noted)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Distribution: V",
"     <sub>",
"      d",
"     </sub>",
"     : Porcine formulation: 2 L (approximately); human formulation: 2.7 L",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Protein binding: 40%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Inactivated by proteolytic enzymes if administered orally",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: Metabolic fate is thought to be hydrolysis to smaller peptides",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life: Porcine formulation: 27 minutes; human formulation: 45 minutes",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Elimination: Clearance: Porcine formulation: 487 &plusmn; 136 mL/minute; human formulation: 580.9 &plusmn; 51.3 mL/minute",
"    </p>",
"   </div>",
"   <div class=\"block adi drugH1Div\" id=\"F1062057\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Additional Information",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     SecreFlo&trade; is available currently as an orphan drug by contacting the manufacturer Repligen; a double-blind crossover study of secretin 0.2 clinical units/kg versus placebo in 56 autistic children revealed no significant differences between the 2 groups (1 clinical unit is equivalent to 0.2 mcg) (Owley, 2001)",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Owley T, McMahon W, Cook EH, et al, &ldquo;Multisite, Double-Blind, Placebo-Controlled Trial of Porcine Secretin in Autism,&rdquo;",
"      <i>",
"       J Am Acad Child Adolesc Psychiatry",
"      </i>",
"      , 2001, 40(11):1293-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?19/45/20179/abstract-text/11699803/pubmed\" id=\"11699803\" target=\"_blank\">",
"        11699803",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 12784 Version 29.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1105-194.187.108.93-F5F47B5EFB-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f19_45_20179=[""].join("\n");
var outline_f19_45_20179=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F220255\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1062048\">",
"      Therapeutic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1062041\">",
"      Dosing: Usual",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F220238\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F220223\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1062052\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1062044\">",
"      Stability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1062051\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F220274\">",
"      Adverse Reactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1062056\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1062040\">",
"      Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13300032\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F220231\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F220233\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F220244\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1062047\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1062050\">",
"      Reference Range",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1062039\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1062054\">",
"      Pharmacodynamics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1062055\">",
"      Pharmacokinetics (Adult data unless noted)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1062057\">",
"      Additional Information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_PED/12784\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_PED/12784|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?27/49/28435?source=related_link\">",
"      Secretin: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?17/24/17795?source=related_link\">",
"      Secretin: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f19_45_20180="Aluminum sulfate calcium acetate: Patient drug information";
var content_f19_45_20180=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Aluminum sulfate calcium acetate: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?0/7/127?source=see_link\">",
"     see \"Aluminum sulfate calcium acetate: Drug information\"",
"    </a>",
"    and",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?2/18/2338?source=see_link\">",
"     see \"Aluminum sulfate calcium acetate: Pediatric drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F132400\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Domeboro&reg; [OTC];",
"     </li>",
"     <li>",
"      Gordon Boro-Packs [OTC];",
"     </li>",
"     <li>",
"      Pedi-Boro&reg; [OTC]",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10017121\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2692076",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat skin irritation.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10017120\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701478",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to aluminum sulfate, calcium acetate, or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10017125\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696817",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not use coverings (bandages, dressings, make-up) unless told to do so by your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697636",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are breast-feeding. You will need to talk about any risks to your baby.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10017126\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698344",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Skin irritation.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10017128\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699049",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad skin irritation.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10017123\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2705324",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         All products:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694772",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take this drug by mouth. Use on your skin only. Keep out of your mouth, nose, and eyes (may burn).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Melt the tablets or the packets in room temperature water as you have been told.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695590",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Rinse affected part with water. Make sure to it dry well.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Stop this drug when health problem is gone.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695589",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Restart this drug if signs show up again.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2705355",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         Compress or wet dressing:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696257",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Wash your hands before and after use.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695609",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Soak a clean, white cloth (eg, diaper, handkerchief, sheet) with the solution.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694494",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Put the cloth on the affected part.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695348",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       You may cover with a dry towel.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695584",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Repeat every 15 to 30 minutes or as needed.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2705552",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         Soaks:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695649",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Soak affected part for 15 to 30 minutes.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695582",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Repeat 3 times a day or as needed.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10017124\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696441",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Put on a missed dose as soon as you think about it.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696549",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Many times this drug is used on an as needed basis.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10017129\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699336",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store at room temperature.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699649",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not use the solution more than 1 time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699172",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Domeboro&reg;: Throw away part not used after 7 days.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10017130\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 12378 Version 32.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-115.66.252.144-EC2EE36D8B-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f19_45_20180=[""].join("\n");
var outline_f19_45_20180=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F132400\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10017121\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10017120\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10017125\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10017126\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10017128\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10017123\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10017124\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10017129\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10017130\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?0/7/127?source=related_link\">",
"      Aluminum sulfate calcium acetate: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?2/18/2338?source=related_link\">",
"      Aluminum sulfate calcium acetate: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f19_45_20181="Doppler umbilical cord prolapse";
var content_f19_45_20181=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F65216&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F65216&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 488px\">",
"   <div class=\"ttl\">",
"    Transabdominal ultrasound using color flow doppler demonstrating the presence of the umbilical cord (funic presentation) just above the cervical canal",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 468px; height: 360px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f19_45_20181=[""].join("\n");
var outline_f19_45_20181=null;
var title_f19_45_20182="Maraviroc: Drug information";
var content_f19_45_20182=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"1\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Maraviroc: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?42/15/43252?source=see_link\">",
"    see \"Maraviroc: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"block black-box-warn drugH1Div\" id=\"F5709027\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     ALERT: U.S. Boxed Warning",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     The FDA-approved labeling includes a boxed warning. See Warnings/Precautions section for a concise summary of this information.  For verbatim wording of the boxed warning, consult the product labeling or",
"     <a href=\"file://www.fda.gov\" target=\"_blank\">",
"      www.fda.gov",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F5185765\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Selzentry&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F5374159\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Celsentri&trade;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F5185769\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Antiretroviral Agent, CCR5 Antagonist",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F5185806\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     HIV treatment: Oral: 300 mg twice daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Dosage adjustment for concomitant CYP3A4 inhibitors/inducers:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <i>",
"      CYP3A inhibitors (with or without a CYP3A4 inducer):",
"     </i>",
"     150 mg twice daily; dose recommended when maraviroc administered concomitantly with strong CYP3A inhibitors including (but not limited to) protease inhibitors (excluding tipranavir/ritonavir), delavirdine, ketoconazole, itraconazole, clarithromycin, nefazodone, and telithromycin.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <i>",
"      CYP3A inducers (without a strong CYP3A4 inhibitor):",
"     </i>",
"     600 mg twice daily; dose recommended when maraviroc administered concomitantly with CYP3A inducers including (but not limited to) efavirenz, etravirine, rifampin, carbamazepine, phenobarbital, and phenytoin",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F5185805\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     HIV treatment: Oral: Adolescents &ge;16 years: Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F5185807\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      <i>",
"       Cl",
"       <sub>",
"        cr",
"       </sub>",
"       &ge;30 mL/minute:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &ge;30 mL/minute and concomitant potent CYP3A4 inhibitors (with or without a CYP3A4 inducer): 150 mg twice daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &ge;30 mL/minute and concomitant potent CYP3A4 inducer (without a CYP3A4 inhibitor): 600 mg twice daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &ge;30 mL/minute and other concomitant medications (eg, tipranavir/ritonavir, nevirapine, raltegravir, all NRTIs, and enfuvirtide): 300 mg twice daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      <i>",
"       Cl",
"       <sub>",
"        cr",
"       </sub>",
"       &lt;30 mL/minute:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &lt;30 mL/minute and concomitant potent CYP3A inhibitors (with or without a CYP3A4 inducer)",
"     <b>",
"      or",
"     </b>",
"     concomitant potent CYP3A4 inducer (without a CYP3A4 inhibitor): Not recommended",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &lt;30 mL/minute and other concomitant medications (eg, tipranavir/ritonavir, nevirapine, raltegravir, all NRTIs, and enfuvirtide): 300 mg twice daily. If postural hypotension occurs, reduce dose to 150 mg twice daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &lt;30 mL/minute and experiencing postural hypotension: Reduce dose to 150 mg twice daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      ESRD requiring intermittent hemodialysis (IHD):",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     With concomitant potent CYP3A inhibitors (with or without a CYP3A4 inducer) or concomitant potent CYP3A4 inducer (without a CYP3A4 inhibitor): Not recommended.",
"     <b>",
"      Note:",
"     </b>",
"     Hemodialysis has minimal effect on clearance.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     With other concomitant medications (eg, tipranavir/ritonavir, nevirapine, raltegravir, all NRTIs, and enfuvirtide): 300 mg twice daily. If postural hypotension occurs, reduce dose to 150 mg twice daily.",
"     <b>",
"      Note:",
"     </b>",
"     Hemodialysis has minimal effect on clearance.",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F5185808\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mild-to-moderate impairment: Use caution; maraviroc concentrations are increased although dosage adjustment is not recommended.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Moderate impairment (with concomitant strong CYP3A4 inhibitor): Use caution; maraviroc concentrations may be increased; monitor closely for adverse events.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Severe impairment: No dosage adjustment provided in manufacturer's labeling (has not been studied).",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F5185813\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Selzentry&reg;: 150 mg, 300 mg",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F5185767\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block meg drugH1Div\" id=\"F7874841\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Guide",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     An FDA-approved patient medication guide, which is available with the product information and at",
"     <a href=\"file://www.fda.gov/downloads/Drugs/DrugSafety/ucm089122.pdf\" target=\"_blank\">",
"      file://www.fda.gov/downloads/Drugs/DrugSafety/ucm089122.pdf",
"     </a>",
"     , must be dispensed with this medication.",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F5185809\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Administer without regards to meals.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F5185770\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of CCR5-tropic HIV-1 infection, in combination with other antiretroviral agents",
"    </p>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F5185781\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     &gt;10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Central nervous system: Fever (13%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Dermatologic: Rash (11%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Respiratory: Upper respiratory tract infection (23%), cough (14%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     2% to 10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Cardiovascular: Vascular hypertensive disorder (3%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Central nervous system: Dizziness (9%; including postural dizziness), insomnia (8%), anxiety (4%), consciousness disturbances (4%), depression (4%), pain (4%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Dermatologic: Folliculitis (4%), pruritus (4%), skin neoplasms (benign; 3%), erythema (2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Endocrine &amp; metabolic: Lipodystrophy (3%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Gastrointestinal: Appetite disorders (8%), constipation (6%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Genitourinary: Urinary tract/bladder symptoms (3% to 5%), genital warts (2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Hematologic: Neutropenia (grades 3/4: 4%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Hepatic: Transaminases increased (grades 3/4: 3% to 5%), bilirubin increased (grades 3/4: 6%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Neuromuscular &amp; skeletal: Joint disorders (7%), paresthesia (5%), peripheral neuropathy (4%), sensory abnormality (4%), muscle pain (3%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Ocular: Conjunctivitis (2%), infection/inflammation (2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Otic: Otitis media (2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Respiratory: Bronchitis (7%), sinusitis (7%), respiratory tract/sinus disorder (3% to 6%), breathing abnormality (4%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Miscellaneous: Herpes infection (8%), sweat gland disturbances (5%), influenza (2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     &lt;2% (Limited to important or life-threatening): Acute cardiac failure, anal cancer, angina, basal cell carcinoma, bile duct neoplasm, bone marrow depression, cerebrovascular accident, cholestatic jaundice, coronary artery disease, coronary artery occlusion, creatine kinase increased, endocarditis, endocrine neoplasm, esophageal carcinoma, hepatic cirrhosis, hepatic failure, hepatotoxicity, hypoplastic anemia, liver metastases, lymphoma, MI, myocardial ischemia, myositis, osteonecrosis, pneumonia, portal vein thrombosis, rhabdomyolysis, seizure, septic shock, squamous cell carcinoma, Stevens-Johnson syndrome, syncope, T-cell lymphoma, tongue neoplasm, tremor, viral meningitis",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F5185776\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Patients with severe renal impairment (Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &lt;30 mL/minute) or end-stage renal disease (ESRD) who are taking potent CYP3A4 inhibitors or inducers",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Canadian labeling: Additional contraindications (not in U.S. labeling): Hypersensitivity to maraviroc or any component of the formulation",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F5185777\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Hepatotoxicity:",
"     <b>",
"      [U.S. Boxed Warning]: Possible drug-induced hepatotoxicity with allergic type features has been reported;",
"     </b>",
"     hepatotoxicity (usually after 1 month of treatment) may be preceded by allergic type reactions (eg, pruritic rash, eosinophilia, fever, and/or increased IgE, excluding rash alone or Stevens-Johnson syndrome [DHHS, 2013]) and/or hepatic adverse events (transaminase increases or signs/symptoms of hepatitis); some cases have been life-threatening; immediately evaluate patients with signs and symptoms of allergic reaction or hepatitis (with or without allergy symptoms). Use with caution in patients with preexisting hepatic dysfunction or coinfection with HBV or HCV, however symptoms have occurred in the absence of preexisting hepatic conditions. Monitor hepatic function at baseline and as clinically indicated during treatment. Consider discontinuation in any patient with possible hepatitis or with elevated transaminases combined with systemic allergic events.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Immune reconstitution syndrome: Patients may develop immune reconstitution syndrome resulting in the occurrence of an inflammatory response to an indolent or residual opportunistic infection during initial HIV treatment or activation of autoimmune disorders (eg, Graves&rsquo; disease, polymyositis, Guillain-Barr&eacute; syndrome) later in therapy; further evaluation and treatment may be required.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Infections: Monitor closely for signs/symptoms of developing infections; use associated with a small increase of certain upper respiratory tract infections and herpes virus infections during clinical trials.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Postural hypotension: Symptomatic postural hypotension has occurred; use caution in patients at risk for postural hypotension due to concomitant medication or history of condition. Patients with severe renal dysfunction who experience postural hypotension should have dose reduced.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Skin and hypersensitivity reactions: Severe and life-threatening skin and hypersensitivity reactions, including Stevens-Johnson syndrome, toxic epidermal necrolysis and drug rash with eosinophilia with systemic symptoms (DRESS), have been reported with use, predominately in patients also receiving concomitant agents associated with these reactions. Rash and constitutional findings (eg, fever, muscle aches, conjunctivitis, oral lesions), with or without organ dysfunction (including hepatic failure), have also accompanied these reports. Discontinue maraviroc and any other suspected agent immediately if symptoms or signs of hypersensitivity occur. Monitor liver function tests and clinical status as appropriate.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Cardiovascular disease: Use with caution in patients with cardiovascular disease or cardiac risk factors. During trials, a small increase in cardiovascular events (myocardial ischemia and/or infarction) occurred in treated patients compared to placebo, although a contributory relationship relative to therapy is unknown. Of note, patients experiencing events generally had cardiac disease/risk factors prior to therapy.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Hepatic impairment: Use caution in patients with HBV or HCV coinfection or with mild-to-moderate hepatic impairment; maraviroc concentrations are increased; no dosage adjustment recommended. Maraviroc concentrations are further increased in patients with moderate hepatic impairment receiving concomitant strong CYP3A inhibitors; monitor closely for adverse events. Use in patients with severe hepatic impairment has not been studied.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Renal impairment: Renal impairment may increase maraviroc concentrations. Use with caution in patients with mild-to-moderate renal impairment.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      <i>",
"       Concurrent drug therapy issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for more detailed information.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Appropriate use: Prior to therapy, coreceptor tropism testing should be performed for presence of CCR5-tropic only virus HIV-1 infection. Therapy not recommended for use in patients with CXCR4- or dual/mixed tropic HIV-1 infection; efficacy not demonstrated in this population. In studies with treatment-naive patients, virologic failure and emergent lamivudine resistance was more common in maraviroc-treated patients compared to patients receiving efavirenz.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F5185788\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Substrate",
"     </b>",
"     of CYP3A4 (major), P-glycoprotein;",
"     <b>",
"      Note:",
"     </b>",
"     Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F5185787\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inducers (Strong): May decrease the serum concentration of Maraviroc. Management: Increase maraviroc adult dose to 600 mg twice daily when used with strong CYP3A4 inducers. This does not apply to patients also receiving strong CYP3A4 inhibitors. Do not use maraviroc with strong CYP3A4 inducers in patients with Clcr less than 30 mL/min.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inhibitors (Moderate): May decrease the metabolism of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inhibitors (Strong): May increase the serum concentration of Maraviroc. Management: Reduce the adult dose of maraviroc to 150 mg twice daily when used with a strong CYP3A4 inhibitor.  Do not use maraviroc with strong CYP3A4 inhibitors in patients with Clcr less than 30 mL/min.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dasatinib: May increase the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Deferasirox: May decrease the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ivacaftor: May increase the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mifepristone: May increase the serum concentration of CYP3A4 Substrates. Management: Minimize doses of CYP3A4 substrates, and monitor for increased concentrations/toxicity, during and 2 weeks following treatment with mifepristone. Avoid cyclosporine, dihydroergotamine, ergotamine, fentanyl, pimozide, quinidine, sirolimus, and tacrolimus.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     St Johns Wort: May decrease the serum concentration of Maraviroc.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tocilizumab: May decrease the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F5185791\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Ethanol/Nutrition/Herb Interactions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Herb/Nutraceutical: St. John&rsquo;s wort may decrease maraviroc concentrations leading to loss of therapeutic efficacy and potentially increased risk of resistance; concomitant use not recommended.",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F5185771\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     B (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F5185772\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Adverse fetal effects were not observed in animal reproduction studies. It is not known if maraviroc crosses the placenta. The DHHS Perinatal HIV Guidelines note there are insufficient data to recommend use in pregnancy.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Regardless of CD4 count or HIV RNA copy number, all HIV-infected pregnant women should receive a combination antepartum antiretroviral (ARV) drug regimen; this includes women who require therapy for their own health, as well as women who do not yet require therapy for their own health. ARV therapy should be started as soon as possible if required for the woman&rsquo;s health. Although earlier initiation may be more effective in reducing the perinatal transmission of HIV, also consider maternal conditions (eg, nausea and vomiting) and the potential risks of first trimester fetal exposure for specific agents. Plasma HIV RNA levels should be assessed at ~34-36 weeks gestation in order to help determine mode of delivery. If ARV therapy must be interrupted for &lt;24 hours during the peripartum period, stop then restart all medications simultaneously in order to decrease the chance of developing resistance. Long-term follow-up is recommended for all infants exposed to ARV medications.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Healthcare providers are encouraged to enroll pregnant women exposed to antiretroviral medications in the Antiretroviral Pregnancy Registry (1-800-258-4263 or www.APRegistry.com). Healthcare providers caring for HIV-infected women and their infants may contact the National Perinatal HIV Hotline (888-448-8765) for clinical consultation (DHHS [perinatal], 2012).",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F5185774\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excretion in breast milk unknown/contraindicated",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F5185775\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     It is not known if maraviroc is excreted into breast milk. Maternal or infant antiretroviral therapy does not completely eliminate the risk of postnatal HIV transmission. In addition, multiclass-resistant virus has been detected in breast-feeding infants despite maternal therapy. Therefore, in the United States, where formula is accessible, affordable, safe, and sustainable, and the risk of infant mortality due to diarrhea and respiratory infections is low, complete avoidance of breast-feeding by HIV-infected women is recommended to decrease potential transmission of HIV (DHHS [perinatal], 2012).",
"    </p>",
"   </div>",
"   <div class=\"block dic drugH1Div\" id=\"F9526047\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dietary Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     May be taken without regards to meals.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F16324144\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Selzentry Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     150 mg (60): $1297.62",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     300 mg (60): $1297.62",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F5185811\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Viral load, CD4 count, transaminases and bilirubin (prior to initiation and periodically during treatment); signs/symptoms of infection, rash, severe skin reactions,hepatitis and/or allergic reaction; postural hypotension; tropism testing (prior to initiation)",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F6038897\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Celsentri (AR, AU, BE, BR, CH, CL, CN, CO, CZ, DE, DK, EC, EE, FR, GB, GR, HK, IE, IL, IT, NL, NO, NZ, PE, PL, PT, SE, SG, TH, TW)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F5185794\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Maraviroc, a CCR5 antagonist, selectively and reversibly binds to the chemokine (C-C motif receptor 5 [CCR5]) coreceptors located on human CD4 cells. CCR5 antagonism prevents interaction between the human CCR5 coreceptor and the gp120 subunit of the viral envelope glycoprotein, thereby inhibiting gp120 conformational change required for CCR5-tropic HIV-1 fusion with the CD4 cell and subsequent cell entry.",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F5185796\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Distribution: V",
"     <sub>",
"      d",
"     </sub>",
"     : ~194 L",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Protein binding: ~76%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Metabolism: Hepatic, via CYP3A to inactive metabolites",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bioavailability: 23% to 33%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Half-life elimination: 14-18 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Time to peak, plasma: 0.5-4 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Excretion: Urine (~20%, 8% as unchanged drug); feces (76%, 25% as unchanged drug)",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      DHHS Panel on Antiretroviral Guidelines for Adults and Adolescents, &ldquo;Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents, Department of Health and Human Services,&rdquo; February 12, 2013;1-267. Available at",
"      <a href=\"file://aidsinfo.nih.gov/Guidelines/GuidelineDetail.aspx?GuidelineID=7&amp;ClassID=1\" target=\"_blank\">",
"       file://www.aidsinfo.nih.gov",
"      </a>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      DHHS Panel on Treatment of HIV-Infected Pregnant Women and Prevention of Perinatal Transmission, \"Recommendations for Use of Antiretroviral Drugs in Pregnant HIV-1-Infected Women for Maternal Health and Interventions to Reduce Perinatal HIV Transmission in the United States,\"  July 31, 2012. Available at",
"      <a href=\"file://aidsinfo.nih.gov/contentfiles/lvguidelines/perinatalgl.pdf\" target=\"_blank\">",
"       file://aidsinfo.nih.gov/contentfiles/lvguidelines/perinatalgl.pdf",
"      </a>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Dorr P, Westby M, Dobbs S, et al, &ldquo;Maraviroc (UK-427,857), a Potent, Orally Bioavailable, and Selective Small-Molecule Inhibitor of Chemokine Receptor CCR5 with Broad-Spectrum Anti-Human Immunodeficiency Virus Type 1 Activity,&rdquo;",
"      <i>",
"       Antimicrob Agents Chemother",
"      </i>",
"      , 2005, 49(11):4721-32.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?19/45/20182/abstract-text/16251317/pubmed\" id=\"16251317\" target=\"_blank\">",
"        16251317",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Working Group on Antiretroviral Therapy and Medical Management of HIV-Infected Children, &ldquo;Guidelines for the Use of Antiretroviral Agents in Pediatric HIV Infection,&rdquo; August 16, 2010. Available at",
"      <a href=\"file://www.aidsinfo.nih.gov\" target=\"_blank\">",
"       file://www.aidsinfo.nih.gov",
"      </a>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 9445 Version 38.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-183.166.191.243-4563C940AB-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f19_45_20182=[""].join("\n");
var outline_f19_45_20182=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5709027\">",
"      ALERT: U.S. Boxed Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5185765\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5374159\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5185769\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5185806\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5185805\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5185807\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5185808\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5185813\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5185767\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7874841\">",
"      Medication Guide",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5185809\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5185770\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5185781\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5185776\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5185777\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5185788\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5185787\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5185791\">",
"      Ethanol/Nutrition/Herb Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5185771\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5185772\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5185774\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5185775\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9526047\">",
"      Dietary Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16324144\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5185811\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6038897\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5185794\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5185796\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9445\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9445|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?42/15/43252?source=related_link\">",
"      Maraviroc: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f19_45_20183="Pap test Ayre spatula";
var content_f19_45_20183=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F72092&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F72092&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Pap test Ayre spatula",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 381px; height: 432px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Close up view of cross section of upper vagina and cervix with wooden or plastic spatula pressed against cervix, longer end introduced slightly into os. Arrow indicates rotation to obtain ectocervical sample.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: LifeART, Nursing. Copyright &copy;2009 Lippincott Williams &amp; Wilkins. All rights reserved.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f19_45_20183=[""].join("\n");
var outline_f19_45_20183=null;
var title_f19_45_20184="Androgen production and therapy in women";
var content_f19_45_20184=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Androgen production and therapy in women",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?19/45/20184/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?19/45/20184/contributors\">",
"     Laurence C Udoff, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?19/45/20184/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?19/45/20184/contributors\">",
"     Robert L Barbieri, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?19/45/20184/contributors\">",
"     William F Crowley, Jr, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?19/45/20184/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?19/45/20184/contributors\">",
"     Kathryn A Martin, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?19/45/20184/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Aug 31, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;All women produce androgens, which may contribute to maintaining normal ovarian function, bone metabolism, cognition, and sexual behavior. This topic will review androgen production in pre- and postmenopausal women, the possible consequences of androgen deficiency, and the effects of androgen therapy in postmenopausal women. A more detailed discussion of the impact of exogenous androgens for the treatment of female sexual dysfunction is found separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/10/34985?source=see_link\">",
"     \"Sexual dysfunction in women: Management\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     ANDROGEN PRODUCTION",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Premenopausal women",
"    </span>",
"    &nbsp;&mdash;&nbsp;The major androgens in the serum of normal cycling women are dehydroepiandrosterone sulfate (DHEA-S), dehydroepiandrosterone (DHEA), androstenedione (A), testosterone (T), and dihydrotestosterone (DHT) in descending order of serum concentrations [",
"    <a class=\"abstract\" href=\"UTD.htm?19/45/20184/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Though abundant in the circulation, DHEA-S, DHEA, and A may be considered pro-hormones, requiring conversion to T or DHT to express their androgenic effects. Androgens are produced in the adrenal gland, the ovary, and from the peripheral conversion of pro-hormones.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      DHEA-S is produced solely by the adrenal gland at a rate of 3.5 to 20 mg per day [",
"      <a class=\"abstract\" href=\"UTD.htm?19/45/20184/abstract/2\">",
"       2",
"      </a>",
"      ]. Circulating levels are in the range of 75 to 375",
"      <span class=\"nowrap\">",
"       mcg/dL",
"      </span>",
"      (2 to 10",
"      <span class=\"nowrap\">",
"       &micro;mol/L).",
"      </span>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?0/16/263?source=see_link\">",
"       \"Dehydroepiandrosterone and its sulfate\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      DHEA is also produced in the adrenal gland (50 percent), the ovary (20 percent), and from peripheral conversion of DHEA-S (30 percent) with total production rates of 6 to 8 mg per day [",
"      <a class=\"abstract\" href=\"UTD.htm?19/45/20184/abstract/3\">",
"       3",
"      </a>",
"      ]. Serum DHEA concentrations range from 0.2 to 0.9",
"      <span class=\"nowrap\">",
"       mcg/dL",
"      </span>",
"      (7 to 31",
"      <span class=\"nowrap\">",
"       nmol/L).",
"      </span>",
"     </li>",
"     <li>",
"      Androstenedione (A) production is split equally between the adrenal gland and the ovary. Daily rates of production are 1.4 to 6.2",
"      <span class=\"nowrap\">",
"       mg/day",
"      </span>",
"      and circulating levels are in the range of 160 to 200",
"      <span class=\"nowrap\">",
"       ng/dL",
"      </span>",
"      (5.6 to 7",
"      <span class=\"nowrap\">",
"       nmol/L)",
"      </span>",
"      [",
"      <a class=\"abstract\" href=\"UTD.htm?19/45/20184/abstract/4,5\">",
"       4,5",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Testosterone (T) is synthesized in the adrenal gland (25 percent), the ovary (25 percent), and from the peripheral conversion of A (50 percent). Daily production rates are in the range of 0.1 to 0.4",
"      <span class=\"nowrap\">",
"       mg/day,",
"      </span>",
"      compared with 5 to7 mg a day in men, and circulating levels are between 20 to 70",
"      <span class=\"nowrap\">",
"       ng/dL",
"      </span>",
"      (0.7 to 2.6",
"      <span class=\"nowrap\">",
"       nmol/L)",
"      </span>",
"      with the lowest concentrations found during the early follicular phase followed by a 20 percent increase at midcycle [",
"      <a class=\"abstract\" href=\"UTD.htm?19/45/20184/abstract/3\">",
"       3",
"      </a>",
"      ]. Nearly all (99 percent) of circulating T is protein-bound (mainly to sex hormone binding globulin [SHBG]) [",
"      <a class=\"abstract\" href=\"UTD.htm?19/45/20184/abstract/6\">",
"       6",
"      </a>",
"      ]. Therefore, any impact on SHBG concentration (eg, oral estrogen-mediated increase in SHBG) affects the concentration of",
"      <span class=\"nowrap\">",
"       free/active",
"      </span>",
"      testosterone. Sex hormone binding globulin (SHBG) normally decreases after menopause, at least partially due to the decline in serum estradiol.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Lastly, DHT is largely an intracellular androgen. DHT is produced within target cells by the 5 alpha reduction of testosterone. DHT acts within the cell and little DHT re-enters the circulation, hence the serum concentration is relatively low [",
"    <a class=\"abstract\" href=\"UTD.htm?19/45/20184/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    All the major androgens are metabolized and excreted into the urine almost exclusively as 17-ketosteroids.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Effect of age and menopause",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cross-sectional and longitudinal studies suggest that serum androgen concentrations (total and free testosterone, and androstenedione) gradually decline in women of reproductive age, with no further decrease after clinical menopause [",
"    <a class=\"abstract\" href=\"UTD.htm?19/45/20184/abstract/8-11\">",
"     8-11",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The secretion and serum concentrations of both DHEA and its sulfate decrease markedly with age from the third decade onward, so that in 70- to 80-year-olds, serum concentrations of both are about 20 percent of those in persons 20 to 30 years old [",
"    <a class=\"abstract\" href=\"UTD.htm?19/45/20184/abstract/8,12\">",
"     8,12",
"    </a>",
"    ]. In women, this decline is accompanied by a substantial fall in urinary 17-ketosteroid (17-KS) excretion (",
"    <a class=\"graphic graphic_figure graphicRef73628 \" href=\"UTD.htm?20/25/20894\">",
"     figure 1",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/16/263?source=see_link\">",
"     \"Dehydroepiandrosterone and its sulfate\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/60/21445?source=see_link&amp;anchor=H2#H2\">",
"     \"Measurement of adrenal androgens\", section on 'Serum DHEA and DHEA sulfate'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The vast majority of evidence, with the exception of one study [",
"    <a class=\"abstract\" href=\"UTD.htm?19/45/20184/abstract/13\">",
"     13",
"    </a>",
"    ], suggests that the postmenopausal ovary is a major androgen-producing gland [",
"    <a class=\"abstract\" href=\"UTD.htm?19/45/20184/abstract/14-25\">",
"     14-25",
"    </a>",
"    ]. Ovarian testosterone production remains relatively constant after natural menopause, thereby increasing the relative ovarian contribution to overall testosterone production [",
"    <a class=\"abstract\" href=\"UTD.htm?19/45/20184/abstract/14\">",
"     14",
"    </a>",
"    ]. These observations are substantiated by the larger ovarian-to-peripheral serum gradient of testosterone in postmenopausal than in premenopausal women [",
"    <a class=\"abstract\" href=\"UTD.htm?19/45/20184/abstract/26\">",
"     26",
"    </a>",
"    ], and by the 40 to 50 percent decrease in serum testosterone concentration seen after oophorectomy in postmenopausal women [",
"    <a class=\"abstract\" href=\"UTD.htm?19/45/20184/abstract/15\">",
"     15",
"    </a>",
"    ], a change that persists over time [",
"    <a class=\"abstract\" href=\"UTD.htm?19/45/20184/abstract/16\">",
"     16",
"    </a>",
"    ]. The relatively high rate of androgen production in the postmenopausal ovary is due to the increase in gonadotropin secretion, which stimulates steroidogenesis in ovarian hilar cells or luteinized stromal cells [",
"    <a class=\"abstract\" href=\"UTD.htm?19/45/20184/abstract/19\">",
"     19",
"    </a>",
"    ]. Ovarian stromal tissue has receptors for both follicle-stimulating hormone and luteinizing hormone [",
"    <a class=\"abstract\" href=\"UTD.htm?19/45/20184/abstract/17,20\">",
"     17,20",
"    </a>",
"    ], and chorionic gonadotropin (hCG) stimulates androstenedione, estradiol, and progesterone secretion by isolated ovarian cortical stromal and hilar cells [",
"    <a class=\"abstract\" href=\"UTD.htm?19/45/20184/abstract/21,22\">",
"     21,22",
"    </a>",
"    ]. In addition, postmenopausal women given hCG have a small increase in serum testosterone [",
"    <a class=\"abstract\" href=\"UTD.htm?19/45/20184/abstract/23\">",
"     23",
"    </a>",
"    ], but not estradiol, concentrations [",
"    <a class=\"abstract\" href=\"UTD.htm?19/45/20184/abstract/25\">",
"     25",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     PHYSIOLOGIC ROLE OF ANDROGENS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Androgens play a critical role in male reproductive development and function. The precise role of androgens in female reproduction is less well studied, but they are essential precursors for estrogen synthesis, and they appear to play an important role in follicular development. Genetic studies using androgen-receptor knockout (ARKO) mouse models have demonstrated that androgens are an important regulator of normal follicle maturation [",
"    <a class=\"abstract\" href=\"UTD.htm?19/45/20184/abstract/27-29\">",
"     27-29",
"    </a>",
"    ], as these mice have lower follicle numbers and develop a premature ovarian failure (POF)-type picture.",
"   </p>",
"   <p>",
"    It has also been proposed that androgens play a role in female sexual function, but the magnitude of the role is uncertain [",
"    <a class=\"abstract\" href=\"UTD.htm?19/45/20184/abstract/30\">",
"     30",
"    </a>",
"    ]. The assertion that low androgen levels play a role in female sexual function is based upon the known role of androgens in male sexuality as well as clinical trials of exogenous testosterone in postmenopausal women in which supraphysiologic doses exerted a positive influence on some aspects of female sexuality. However, in studies that measure serum hormone levels and sexual function in women, the correlation between androgen concentrations and sexual function is either weak or nonexistent. In addition, women with hyperandrogenism (eg, polycystic ovary syndrome) do not exhibit beneficial sexual effects (although women with severe hyperandrogenism from ovarian or adrenal androgen-secreting tumors sometimes experience intrusive sexual thoughts). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/42/25258?source=see_link&amp;anchor=H5#H5\">",
"     \"Sexual dysfunction in women: Epidemiology, risk factors, and evaluation\", section on 'Role of androgens'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Androgen receptors are found in many other tissues in women including the vasculature [",
"    <a class=\"abstract\" href=\"UTD.htm?19/45/20184/abstract/31,32\">",
"     31,32",
"    </a>",
"    ], brain [",
"    <a class=\"abstract\" href=\"UTD.htm?19/45/20184/abstract/33\">",
"     33",
"    </a>",
"    ], breast, skin, muscle, adipose, and bone [",
"    <a class=\"abstract\" href=\"UTD.htm?19/45/20184/abstract/34-36\">",
"     34-36",
"    </a>",
"    ], suggesting that androgens have nonreproductive functions, as well (see",
"    <a class=\"local\" href=\"#H75832548\">",
"     'Other possible benefits'",
"    </a>",
"    below and",
"    <a class=\"local\" href=\"#H15\">",
"     'Risks and side effects'",
"    </a>",
"    below). These include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Possible adverse cardiovascular effects &ndash; In women, androgens have been thought to be atherogenic, largely based upon on the higher rates of cardiovascular disease in men compared to women, and the possible higher risk in women with androgen excess (eg, polycystic ovary syndrome) compared to normal women [",
"      <a class=\"abstract\" href=\"UTD.htm?19/45/20184/abstract/37,38\">",
"       37,38",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?28/36/29258?source=see_link\">",
"       \"Postmenopausal hormone therapy and cardiovascular risk\"",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      One proposed mechanism by which androgens may adversely affect the risk of cardiovascular disease is through a decrease in serum high-density lipoprotein (HDL) cholesterol concentrations. Women with PCOS are more likely to have lower HDL, higher triglycerides, higher LDL, and an increase in small dense LDL particles when compared with women of similar body mass index and insulin resistance without polycystic ovary syndrome (PCOS) [",
"      <a class=\"abstract\" href=\"UTD.htm?19/45/20184/abstract/39-43\">",
"       39-43",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Possible beneficial effects on bone health &ndash; In men, both androgens and estrogens regulate skeletal homeostasis, but the relative magnitude of each hormonal effect is unknown. In women, estrogen is the primary sex steroid regulator of bone. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?3/53/3929?source=see_link&amp;anchor=H15652976#H15652976\">",
"       \"Pathogenesis of osteoporosis\", section on 'Estrogen'",
"      </a>",
"      .) Low serum androgen concentrations have been associated with lower bone density and an increase in fracture risk in some studies [",
"      <a class=\"abstract\" href=\"UTD.htm?19/45/20184/abstract/44-47\">",
"       44-47",
"      </a>",
"      ], but an effect of exogenous testosterone on bone mineral density or fracture risk has not been demonstrated. (See",
"      <a class=\"local\" href=\"#H75832548\">",
"       'Other possible benefits'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      Possible effects on mood and cognitive function &ndash; The role of endogenous androgens on mood and cognition in women is not known. Short-term administration of supraphysiologic doses of testosterone does not appear to have a major effect on either parameter. (See",
"      <a class=\"local\" href=\"#H75832548\">",
"       'Other possible benefits'",
"      </a>",
"      below.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     ANDROGEN DEFICIENCY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Women with low levels of circulating androgens are said to have androgen deficiency or androgen insufficiency syndrome. However, there are no clear biochemical criteria for this syndrome. Measurement of serum androgen concentrations, in particular, free testosterone, is problematic because of a lack of validated assays in the female range (much lower than the male range), age-based normative data are limited [",
"    <a class=\"abstract\" href=\"UTD.htm?19/45/20184/abstract/48\">",
"     48",
"    </a>",
"    ], and serum androgen concentrations do not appear to be an independent predictor of sexual function in women [",
"    <a class=\"abstract\" href=\"UTD.htm?19/45/20184/abstract/49-53\">",
"     49-53",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    An Endocrine Society Clinical Practice Guideline recommended against making a diagnosis of androgen deficiency because of the lack of both a well-defined clinical syndrome and age-based normative data for serum testosterone and free testosterone concentrations. That said, there are a number of conditions that may represent androgen deficiency syndromes:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Bilateral oophorectomy",
"     </li>",
"     <li>",
"      Primary adrenal insufficiency",
"     </li>",
"     <li>",
"      Hypopituitarism, particularly women with both ACTH and gonadotropin deficiency [",
"      <a class=\"abstract\" href=\"UTD.htm?19/45/20184/abstract/54\">",
"       54",
"      </a>",
"      ]",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Medications including oral contraceptives and glucocorticoids may cause a relative androgen deficiency due to ovarian and adrenal androgen suppression, respectively. Oral estrogens, even at low doses (menopausal replacement) reduce serum free testosterone concentrations by increasing serum SHBG levels. Women with anorexia nervosa have lower serum concentrations of total and free testosterone, but not DHEAS concentrations when compared with normal-weight women with hypothalamic amenorrhea or healthy controls [",
"    <a class=\"abstract\" href=\"UTD.htm?19/45/20184/abstract/55\">",
"     55",
"    </a>",
"    ]. In this report, women with anorexia nervosa who were taking oral contraceptives had the lowest concentrations of free testosterone and DHEAS.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     EFFECTS OF EXOGENOUS ANDROGENS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The effects of exogenous androgen administration on sexual function, vasomotor symptoms, cognitive function, and bone are described here; effects on sexual function and available products are reviewed in greater detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/10/34985?source=see_link&amp;anchor=H23#H23\">",
"     \"Sexual dysfunction in women: Management\", section on 'Available androgen preparations and limitations'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3232316\">",
"    <span class=\"h2\">",
"     Exogenous testosterone",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Sexual function",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H162185108\">",
"    <span class=\"h4\">",
"     Postmenopausal women",
"    </span>",
"    &nbsp;&mdash;&nbsp;Menopause is associated with dyspareunia due to vaginal atrophy, which results from estrogen deficiency. Otherwise, the effects of age and menopause on female sexual function vary considerably among women. Although serum androgen concentrations do not correlate with sexual function in women, testosterone therapy has been shown to improve female sexual function in carefully selected populations of postmenopausal women. In trials of postmenopausal women who developed hypoactive sexual desire disorder after undergoing bilateral oophorectomy, the addition of transdermal testosterone to estrogen therapy improved sexual desire, arousal, and orgasmic response. Side effects include acne and hirsutism. However, the doses of testosterone used are supraphysiologic, and mean serum concentrations of testosterone are at the upper limit of normal for premenopausal women. The long-term consequences of these relatively high serum testosterone concentrations are unknown. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/10/34985?source=see_link&amp;anchor=H21#H21\">",
"     \"Sexual dysfunction in women: Management\", section on 'Androgens'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A transdermal testosterone preparation (300 mcg patch) that is applied twice weekly is available in some countries, but not the US. Additional details on its efficacy and clinical monitoring are reviewed in detail separately.",
"   </p>",
"   <p>",
"    Androgen replacement therapy has been advocated by some for postmenopausal women with decreased sexual desire associated with personal distress and with no other identifiable cause [",
"    <a class=\"abstract\" href=\"UTD.htm?19/45/20184/abstract/56,57\">",
"     56,57",
"    </a>",
"    ]. Given the lack of a well-defined clinical syndrome, age-based normative data for serum testosterone concentrations, and long-term safety data for testosterone preparations, we agree with the Endocrine Society guidelines and currently do not suggest the routine use of androgen therapy in women [",
"    <a class=\"abstract\" href=\"UTD.htm?19/45/20184/abstract/51\">",
"     51",
"    </a>",
"    ]. However, for postmenopausal women with hypoactive sexual desire disorder in whom nonpharmacologic therapy has been unsuccessful, a trial of testosterone&nbsp;is reasonable. Candidates for therapy must have no contraindications to taking testosterone and be willing to accept androgenic side effects. As noted, there are no approved products available in the US. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/10/34985?source=see_link&amp;anchor=H21#H21\">",
"     \"Sexual dysfunction in women: Management\", section on 'Androgens'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H348552700\">",
"    <span class=\"h4\">",
"     Premenopausal women",
"    </span>",
"    &nbsp;&mdash;&nbsp;The role of exogenous testosterone administration in otherwise healthy premenopausal women with sexual dysfunction is not well studied. We suggest against the use of androgen therapy in this patient population. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/10/34985?source=see_link&amp;anchor=H21#H21\">",
"     \"Sexual dysfunction in women: Management\", section on 'Androgens'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h4\">",
"     Women with hypopituitarism",
"    </span>",
"    &nbsp;&mdash;&nbsp;Women with hypopituitarism, in particular those with both ACTH and gonadotropin deficiency, may benefit from testosterone therapy. In a trial of women with androgen deficiency due to hypopituitarism, treatment with 150 to 300 mcg of testosterone transdermally daily for one year improved overall sexual function (as judged by a questionnaire) by a small but statistically significant amount, but only when the serum testosterone concentration was increased to the upper limit of normal for women [",
"    <a class=\"abstract\" href=\"UTD.htm?19/45/20184/abstract/58\">",
"     58",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/22/28006?source=see_link&amp;anchor=H151093784#H151093784\">",
"     \"Treatment of hypopituitarism\", section on 'Androgen replacement'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H75832548\">",
"    <span class=\"h3\">",
"     Other possible benefits",
"    </span>",
"    &nbsp;&mdash;&nbsp;Androgen therapy had been reported in uncontrolled studies in the past to be beneficial for vasomotor flushes, cognitive function and mood, and bone mineral density. However, in a systematic review and meta-analyses of 54 studies, no evidence of benefit for any of these outcomes was observed [",
"    <a class=\"abstract\" href=\"UTD.htm?19/45/20184/abstract/59\">",
"     59",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h3\">",
"     Risks and side effects",
"    </span>",
"    &nbsp;&mdash;&nbsp;In reviews of available testosterone clinical trials, hirsutism and acne appeared to be the major adverse reactions (both were dose- and duration-related and generally reversible) [",
"    <a class=\"abstract\" href=\"UTD.htm?19/45/20184/abstract/59,60\">",
"     59,60",
"    </a>",
"    ]. Virilization and voice deepening are rare complications [",
"    <a class=\"abstract\" href=\"UTD.htm?19/45/20184/abstract/60\">",
"     60",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/10/34985?source=see_link\">",
"     \"Sexual dysfunction in women: Management\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    All available trials are limited by their short duration (&le;2 years) and the co-administration of estrogen or estrogen-progestin therapy. However, it appears that oral (but not parental or transdermal) testosterone is associated with a decrease in serum HDL concentrations, which could have a negative impact on cardiovascular risk. In one review, no adverse effects on blood pressure, vascular reactivity, blood viscosity, hemoglobin concentration, coagulation factors or insulin sensitivity were described.",
"   </p>",
"   <p>",
"    Two studies have looked at the effects of testosterone administration on brachial artery vasodilatation in postmenopausal women on postmenopausal hormone therapy (HT) [",
"    <a class=\"abstract\" href=\"UTD.htm?19/45/20184/abstract/61\">",
"     61",
"    </a>",
"    ]. In 33 postmenopausal women on HT compared with 15 controls, both endothelial-dependent and -independent brachial artery vasodilatation was improved by the addition of a testosterone implant (50 mg) for six weeks. Similar results were shown in a second report of 60 postmenopausal women [",
"    <a class=\"abstract\" href=\"UTD.htm?19/45/20184/abstract/62\">",
"     62",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Most androgens are aromatized to estrogens, thus risks of estrogen therapy are also possible with androgen treatment. Some women on testosterone develop abnormal uterine bleeding. Although there is no evidence of an increased risk of endometrial hyperplasia or cancer, data on long-term use and risk are limited. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/10/34985?source=see_link&amp;anchor=H21#H21\">",
"     \"Sexual dysfunction in women: Management\", section on 'Androgens'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Mammographic density does not appear to be affected by the addition of testosterone to estrogen therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?19/45/20184/abstract/63\">",
"     63",
"    </a>",
"    ]. The effect of testosterone on breast cancer risk is unknown. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/11/11449?source=see_link&amp;anchor=H150020386#H150020386\">",
"     \"Postmenopausal hormone therapy and the risk of breast cancer\", section on 'Effect of testosterone'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1649922\">",
"    <span class=\"h2\">",
"     Androstenedione",
"    </span>",
"    &nbsp;&mdash;&nbsp;Androstenedione, an androgen precursor that is widely used and promoted as &ldquo;Andro&rdquo; in bodybuilding magazines, increases serum testosterone concentrations in some men, but does not improve muscle strength. When administered acutely to women, androstenedione increases serum testosterone and estrone concentrations [",
"    <a class=\"abstract\" href=\"UTD.htm?19/45/20184/abstract/64\">",
"     64",
"    </a>",
"    ]. However, the impact of regular use on sexual function or its potential androgenic side effects in women are unknown. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/35/21050?source=see_link&amp;anchor=H7#H7\">",
"     \"Use of androgens and other hormones to enhance athletic performance\", section on 'Androgen precursors'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3232275\">",
"    <span class=\"h2\">",
"     Adrenal androgen replacement",
"    </span>",
"    &nbsp;&mdash;&nbsp;DHEA replacement therapy appears to be effective for improving sense of well-being and insulin sensitivity, while preventing bone loss at the femoral neck in women with adrenal androgen deficiency, including those with primary adrenal insufficiency, hypopituitarism (ACTH deficiency), and chronic glucocorticoid use. Other effects of DHEA therapy in this population are reviewed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/16/263?source=see_link&amp;anchor=H3#H3\">",
"     \"Dehydroepiandrosterone and its sulfate\", section on 'Use in adrenal insufficiency'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/38/41578?source=see_link\">",
"     \"Overview of the therapy and prognosis of systemic lupus erythematosus in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    DHEA supplementation has also been proposed as adjunctive postmenopausal hormone therapy for aging men and women. While there is a well-known decline in serum DHEA and DHEA-S concentrations with age, the role of adrenal androgen replacement in peri- and postmenopausal women is unclear. However, DHEA supplementation in otherwise healthy peri- or postmenopausal women does not appear to have clinical benefits and we therefore suggest against its use. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/16/263?source=see_link\">",
"     \"Dehydroepiandrosterone and its sulfate\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?11/17/11538?source=see_link\">",
"       \"Patient information: Sex problems in women (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?12/4/12357?source=see_link\">",
"       \"Patient information: Sexual problems in women (Beyond the Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?32/4/32835?source=see_link\">",
"       \"Patient information: Postmenopausal hormone therapy (Beyond the Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?31/16/32001?source=see_link\">",
"       \"Patient information: Nonhormonal treatments for menopausal symptoms (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The major androgens in the serum of normal cycling women are dehydroepiandrosterone sulfate (DHEA-S), dehydroepiandrosterone (DHEA), androstenedione (A), testosterone (T), and dihydrotestosterone (DHT) in descending order of serum concentrations. Cross-sectional and longitudinal studies suggest that serum androgen concentrations (total and free testosterone, and androstenedione) gradually decline in women of reproductive age, with no further decrease after clinical menopause. The secretion and serum concentrations of both DHEA and its sulfate decrease markedly with age from the third decade onward, so that in 70- to 80-year-olds, serum concentrations of both are about 20 percent of those in persons 20 to 30 years old. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Androgen production'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Women with low levels of circulating androgens are said to have androgen deficiency or androgen insufficiency syndrome. However, there are no clear biochemical criteria for this syndrome. That said, there are a number of conditions that may represent androgen deficiency syndromes, including bilateral oophorectomy, primary adrenal insufficiency, and hypopituitarism, particularly in women with both ACTH and gonadotropin deficiency. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Androgen deficiency'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Exogenous testosterone therapy has been shown to improve female sexual function (sexual desire, arousal, and orgasmic response) in carefully selected populations of postmenopausal women (those who developed hypoactive sexual desire disorder after undergoing bilateral oophorectomy). (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Sexual function'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Currently available clinical trial data do not suggest that exogenous testosterone therapy has a beneficial effect on bone density, mood, cognition, or vasomotor symptoms. (See",
"      <a class=\"local\" href=\"#H75832548\">",
"       'Other possible benefits'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Serum HDL cholesterol concentrations decline slightly in postmenopausal women receiving oral testosterone therapy, but it is not known if the change substantially affects overall cardiovascular risk. (See",
"      <a class=\"local\" href=\"#H15\">",
"       'Risks and side effects'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Side effects of androgen therapy include hirsutism and acne; they are dose- and duration-dependent, and generally reversible. Virilizing changes are rare. (See",
"      <a class=\"local\" href=\"#H15\">",
"       'Risks and side effects'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Androgen therapy recommendations for women with sexual dysfunction are found separately. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?34/10/34985?source=see_link&amp;anchor=H21#H21\">",
"       \"Sexual dysfunction in women: Management\", section on 'Androgens'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/45/20184/abstract/1\">",
"      Burger HG. Androgen production in women. Fertil Steril 2002; 77 Suppl 4:S3.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/45/20184/abstract/2\">",
"      Endoh, A, Kristiansen, SB, Casson RP, Buser JE, et al. The zona reticularis is the site of biosynthesis of dehydroepiandrosterone and dehydroepiandrosterone sulfate in the adult human adrenal cortex, resulting from its low expression of 3 b-hydroxysteroid dehydrogenase. J Clin Endocrinol Metab 1991; 78:113.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/45/20184/abstract/3\">",
"      Longcope C. Adrenal and gonadal androgen secretion in normal females. Clin Endocrinol Metab 1986; 15:213.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/45/20184/abstract/4\">",
"      Judd HL, Yen SS. Serum androstenedione and testosterone levels during the menstrual cycle. J Clin Endocrinol Metab 1973; 36:475.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/45/20184/abstract/5\">",
"      Horton R, Tait JF. Androstenedione production and interconversion rates measured in peripheral blood and studies on the possible site of its conversion to testosterone. J Clin Invest 1966; 45:301.",
"     </a>",
"    </li>",
"    <li>",
"     Speroff L, Glass RH, Kase NG. Clinical Gynecologic Endocrinology and Infertility, 5th Ed, Williams &amp; Wilkins, Baltimore 1994.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/45/20184/abstract/7\">",
"      Abraham GE. Ovarian and adrenal contribution to peripheral androgens during the menstrual cycle. J Clin Endocrinol Metab 1974; 39:340.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/45/20184/abstract/8\">",
"      Davison SL, Bell R, Donath S, et al. Androgen levels in adult females: changes with age, menopause, and oophorectomy. J Clin Endocrinol Metab 2005; 90:3847.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/45/20184/abstract/9\">",
"      Burger HG, Dudley EC, Cui J, et al. A prospective longitudinal study of serum testosterone, dehydroepiandrosterone sulfate, and sex hormone-binding globulin levels through the menopause transition. J Clin Endocrinol Metab 2000; 85:2832.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/45/20184/abstract/10\">",
"      Elmlinger MW, K&uuml;hnel W, Wormstall H, D&ouml;ller PC. Reference intervals for testosterone, androstenedione and SHBG levels in healthy females and males from birth until old age. Clin Lab 2005; 51:625.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/45/20184/abstract/11\">",
"      Rothman MS, Carlson NE, Xu M, et al. Reexamination of testosterone, dihydrotestosterone, estradiol and estrone levels across the menstrual cycle and in postmenopausal women measured by liquid chromatography-tandem mass spectrometry. Steroids 2011; 76:177.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/45/20184/abstract/12\">",
"      Baulieu EE, Thomas G, Legrain S, et al. Dehydroepiandrosterone (DHEA), DHEA sulfate, and aging: contribution of the DHEAge Study to a sociobiomedical issue. Proc Natl Acad Sci U S A 2000; 97:4279.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/45/20184/abstract/13\">",
"      Couzinet B, Meduri G, Lecce MG, et al. The postmenopausal ovary is not a major androgen-producing gland. J Clin Endocrinol Metab 2001; 86:5060.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/45/20184/abstract/14\">",
"      Adashi EY. The climacteric ovary as a functional gonadotropin-driven androgen-producing gland. Fertil Steril 1994; 62:20.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/45/20184/abstract/15\">",
"      Judd HL, Lucas WE, Yen SS. Effect of oophorectomy on circulating testosterone and androstenedione levels in patients with endometrial cancer. Am J Obstet Gynecol 1974; 118:793.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/45/20184/abstract/16\">",
"      Laughlin GA, Barrett-Connor E, Kritz-Silverstein D, von M&uuml;hlen D. Hysterectomy, oophorectomy, and endogenous sex hormone levels in older women: the Rancho Bernardo Study. J Clin Endocrinol Metab 2000; 85:645.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/45/20184/abstract/17\">",
"      Nakano R, Shima K, Yamoto M, et al. Binding sites for gonadotropins in human postmenopausal ovaries. Obstet Gynecol 1989; 73:196.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/45/20184/abstract/18\">",
"      Meldrum DR, Davidson BJ, Tataryn IV, Judd HL. Changes in circulating steroids with aging in postmenopausal women. Obstet Gynecol 1981; 57:624.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/45/20184/abstract/19\">",
"      Judd HL, Fournet N. Changes of ovarian hormonal function with aging. Exp Gerontol 1994; 29:285.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/45/20184/abstract/20\">",
"      Peluso JJ, Steger RW, Jaszczak S, Hafez ES. Gonadotropin binding sites in human postmenopausal ovaries. Fertil Steril 1976; 27:789.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/45/20184/abstract/21\">",
"      Dennefors BL, Janson PO, Knutson F, Hamberger L. Steroid production and responsiveness to gonadotropin in isolated stromal tissue of human postmenopausal ovaries. Am J Obstet Gynecol 1980; 136:997.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/45/20184/abstract/22\">",
"      Dennefors BL, Janson PO, Hamberger L, Knutsson F. Hilus cells from human postmenopausal ovaries: gonadotrophin sensitivity, steroid and cyclic AMP production. Acta Obstet Gynecol Scand 1982; 61:413.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/45/20184/abstract/23\">",
"      Vermeulen A. The hormonal activity of the postmenopausal ovary. J Clin Endocrinol Metab 1976; 42:247.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/45/20184/abstract/24\">",
"      Poliak A, Jones GE, Woodruff JD. The effect of human chorionic gonadotropin on castrated postmenopausal women. Am J Obstet Gynecol 1971; 109:555.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/45/20184/abstract/25\">",
"      Greenblatt RB, Colle ML, Mahesh VB. Ovarian and adrenal steroid production in the postmenopausal woman. Obstet Gynecol 1976; 47:383.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/45/20184/abstract/26\">",
"      Judd HL, Judd GE, Lucas WE, Yen SS. Endocrine function of the postmenopausal ovary: concentration of androgens and estrogens in ovarian and peripheral vein blood. J Clin Endocrinol Metab 1974; 39:1020.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/45/20184/abstract/27\">",
"      Shiina H, Matsumoto T, Sato T, et al. Premature ovarian failure in androgen receptor-deficient mice. Proc Natl Acad Sci U S A 2006; 103:224.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/45/20184/abstract/28\">",
"      Walters KA, Simanainen U, Handelsman DJ. Molecular insights into androgen actions in male and female reproductive function from androgen receptor knockout models. Hum Reprod Update 2010; 16:543.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/45/20184/abstract/29\">",
"      Gleicher N, Weghofer A, Barad DH. The role of androgens in follicle maturation and ovulation induction: friend or foe of infertility treatment? Reprod Biol Endocrinol 2011; 9:116.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/45/20184/abstract/30\">",
"      Hutchinson KA. Androgens and sexuality. Am J Med 1995; 98:111S.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/45/20184/abstract/31\">",
"      Krause DN, Duckles SP, Gonzales RJ. Local oestrogenic/androgenic balance in the cerebral vasculature. Acta Physiol (Oxf) 2011; 203:181.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/45/20184/abstract/32\">",
"      Eicheler W, Tuohimaa P, Vilja P, et al. Immunocytochemical localization of human 5 alpha-reductase 2 with polyclonal antibodies in androgen target and non-target human tissues. J Histochem Cytochem 1994; 42:667.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/45/20184/abstract/33\">",
"      Puy L, MacLusky NJ, Becker L, et al. Immunocytochemical detection of androgen receptor in human temporal cortex characterization and application of polyclonal androgen receptor antibodies in frozen and paraffin-embedded tissues. J Steroid Biochem Mol Biol 1995; 55:197.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/45/20184/abstract/34\">",
"      Colvard DS, Eriksen EF, Keeting PE, et al. Identification of androgen receptors in normal human osteoblast-like cells. Proc Natl Acad Sci U S A 1989; 86:854.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/45/20184/abstract/35\">",
"      Callewaert F, Sinnesael M, Gielen E, et al. Skeletal sexual dimorphism: relative contribution of sex steroids, GH-IGF1, and mechanical loading. J Endocrinol 2010; 207:127.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/45/20184/abstract/36\">",
"      Vanderschueren D, Vandenput L, Boonen S, et al. Androgens and bone. Endocr Rev 2004; 25:389.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/45/20184/abstract/37\">",
"      Dahlgren E, Janson PO, Johansson S, et al. Polycystic ovary syndrome and risk for myocardial infarction. Evaluated from a risk factor model based on a prospective population study of women. Acta Obstet Gynecol Scand 1992; 71:599.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/45/20184/abstract/38\">",
"      Solomon CG, Hu FB, Dunaif A, et al. Menstrual cycle irregularity and risk for future cardiovascular disease. J Clin Endocrinol Metab 2002; 87:2013.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/45/20184/abstract/39\">",
"      Lo JC, Feigenbaum SL, Yang J, et al. Epidemiology and adverse cardiovascular risk profile of diagnosed polycystic ovary syndrome. J Clin Endocrinol Metab 2006; 91:1357.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/45/20184/abstract/40\">",
"      Legro RS, Kunselman AR, Dunaif A. Prevalence and predictors of dyslipidemia in women with polycystic ovary syndrome. Am J Med 2001; 111:607.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/45/20184/abstract/41\">",
"      Legro RS, Azziz R, Ehrmann D, et al. Minimal response of circulating lipids in women with polycystic ovary syndrome to improvement in insulin sensitivity with troglitazone. J Clin Endocrinol Metab 2003; 88:5137.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/45/20184/abstract/42\">",
"      Berneis K, Rizzo M, Lazzarini V, et al. Atherogenic lipoprotein phenotype and low-density lipoproteins size and subclasses in women with polycystic ovary syndrome. J Clin Endocrinol Metab 2007; 92:186.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/45/20184/abstract/43\">",
"      Phelan N, O'Connor A, Kyaw-Tun T, et al. Lipoprotein subclass patterns in women with polycystic ovary syndrome (PCOS) compared with equally insulin-resistant women without PCOS. J Clin Endocrinol Metab 2010; 95:3933.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/45/20184/abstract/44\">",
"      Longcope C, Baker RS, Hui SL, Johnston CC Jr. Androgen and estrogen dynamics in women with vertebral crush fractures. Maturitas 1984; 6:309.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/45/20184/abstract/45\">",
"      Steinberg KK, Freni-Titulaer LW, DePuey EG, et al. Sex steroids and bone density in premenopausal and perimenopausal women. J Clin Endocrinol Metab 1989; 69:533.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/45/20184/abstract/46\">",
"      Slemenda C, Longcope C, Peacock M, et al. Sex steroids, bone mass, and bone loss. A prospective study of pre-, peri-, and postmenopausal women. J Clin Invest 1996; 97:14.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/45/20184/abstract/47\">",
"      Miller KK, Biller BM, Hier J, et al. Androgens and bone density in women with hypopituitarism. J Clin Endocrinol Metab 2002; 87:2770.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/45/20184/abstract/48\">",
"      Haring R, Hannemann A, John U, et al. Age-specific reference ranges for serum testosterone and androstenedione concentrations in women measured by liquid chromatography-tandem mass spectrometry. J Clin Endocrinol Metab 2012; 97:408.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/45/20184/abstract/49\">",
"      Miller KK, Rosner W, Lee H, et al. Measurement of free testosterone in normal women and women with androgen deficiency: comparison of methods. J Clin Endocrinol Metab 2004; 89:525.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/45/20184/abstract/50\">",
"      Davis SR, Davison SL, Donath S, Bell RJ. Circulating androgen levels and self-reported sexual function in women. JAMA 2005; 294:91.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/45/20184/abstract/51\">",
"      Wierman ME, Basson R, Davis SR, et al. Androgen therapy in women: an Endocrine Society Clinical Practice guideline. J Clin Endocrinol Metab 2006; 91:3697.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/45/20184/abstract/52\">",
"      Rosner W, Auchus RJ, Azziz R, et al. Position statement: Utility, limitations, and pitfalls in measuring testosterone: an Endocrine Society position statement. J Clin Endocrinol Metab 2007; 92:405.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/45/20184/abstract/53\">",
"      Dennerstein L, Dudley EC, Hopper JL, Burger H. Sexuality, hormones and the menopausal transition. Maturitas 1997; 26:83.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/45/20184/abstract/54\">",
"      Miller KK, Sesmilo G, Schiller A, et al. Androgen deficiency in women with hypopituitarism. J Clin Endocrinol Metab 2001; 86:561.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/45/20184/abstract/55\">",
"      Miller KK, Lawson EA, Mathur V, et al. Androgens in women with anorexia nervosa and normal-weight women with hypothalamic amenorrhea. J Clin Endocrinol Metab 2007; 92:1334.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/45/20184/abstract/56\">",
"      Braunstein GD. Androgen insufficiency in women: summary of critical issues. Fertil Steril 2002; 77 Suppl 4:S94.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/45/20184/abstract/57\">",
"      North American Menopause Society. The role of testosterone therapy in postmenopausal women: position statement of The North American Menopause Society. Menopause 2005; 12:496.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/45/20184/abstract/58\">",
"      Miller KK, Biller BM, Beauregard C, et al. Effects of testosterone replacement in androgen-deficient women with hypopituitarism: a randomized, double-blind, placebo-controlled study. J Clin Endocrinol Metab 2006; 91:1683.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/45/20184/abstract/59\">",
"      Somboonporn W, Davis S, Seif MW, Bell R. Testosterone for peri- and postmenopausal women. Cochrane Database Syst Rev 2005; :CD004509.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/45/20184/abstract/60\">",
"      Braunstein GD. Safety of testosterone treatment in postmenopausal women. Fertil Steril 2007; 88:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/45/20184/abstract/61\">",
"      Worboys S, Kotsopoulos D, Teede H, et al. Evidence that parenteral testosterone therapy may improve endothelium-dependent and -independent vasodilation in postmenopausal women already receiving estrogen. J Clin Endocrinol Metab 2001; 86:158.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/45/20184/abstract/62\">",
"      Montalcini T, Gorgone G, Gazzaruso C, et al. Endogenous testosterone and endothelial function in postmenopausal women. Coron Artery Dis 2007; 18:9.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/45/20184/abstract/63\">",
"      Hofling M, Hirschberg AL, Skoog L, et al. Testosterone inhibits estrogen/progestogen-induced breast cell proliferation in postmenopausal women. Menopause 2007; 14:183.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/45/20184/abstract/64\">",
"      Leder BZ, Leblanc KM, Longcope C, et al. Effects of oral androstenedione administration on serum testosterone and estradiol levels in postmenopausal women. J Clin Endocrinol Metab 2002; 87:5449.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 7447 Version 7.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-200.215.4.194-8300F9CC1D-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f19_45_20184=[""].join("\n");
var outline_f19_45_20184=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H17\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      ANDROGEN PRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Premenopausal women",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Effect of age and menopause",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      PHYSIOLOGIC ROLE OF ANDROGENS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      ANDROGEN DEFICIENCY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      EFFECTS OF EXOGENOUS ANDROGENS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3232316\">",
"      Exogenous testosterone",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Sexual function",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H162185108\">",
"      Postmenopausal women",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H348552700\">",
"      Premenopausal women",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Women with hypopituitarism",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H75832548\">",
"      - Other possible benefits",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      - Risks and side effects",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1649922\">",
"      Androstenedione",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3232275\">",
"      Adrenal androgen replacement",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ENDO/7447\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ENDO/7447|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?20/25/20894\" title=\"figure 1\">",
"      Adrenal androgens and age",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/16/263?source=related_link\">",
"      Dehydroepiandrosterone and its sulfate",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/60/21445?source=related_link\">",
"      Measurement of adrenal androgens",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/38/41578?source=related_link\">",
"      Overview of the therapy and prognosis of systemic lupus erythematosus in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/53/3929?source=related_link\">",
"      Pathogenesis of osteoporosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?31/16/32001?source=related_link\">",
"      Patient information: Nonhormonal treatments for menopausal symptoms (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?32/4/32835?source=related_link\">",
"      Patient information: Postmenopausal hormone therapy (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?11/17/11538?source=related_link\">",
"      Patient information: Sex problems in women (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?12/4/12357?source=related_link\">",
"      Patient information: Sexual problems in women (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/36/29258?source=related_link\">",
"      Postmenopausal hormone therapy and cardiovascular risk",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/11/11449?source=related_link\">",
"      Postmenopausal hormone therapy and the risk of breast cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/42/25258?source=related_link\">",
"      Sexual dysfunction in women: Epidemiology, risk factors, and evaluation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/10/34985?source=related_link\">",
"      Sexual dysfunction in women: Management",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/22/28006?source=related_link\">",
"      Treatment of hypopituitarism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/35/21050?source=related_link\">",
"      Use of androgens and other hormones to enhance athletic performance",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f19_45_20185="Biology of vascular calcification in renal failure";
var content_f19_45_20185=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Biology of vascular calcification in renal failure",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?19/45/20185/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?19/45/20185/contributors\">",
"     Behdad Afzali, MRCP",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?19/45/20185/contributors\">",
"     David JA Goldsmith, MA, FRCP",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?19/45/20185/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?19/45/20185/contributors\">",
"     Stanley Goldfarb, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?19/45/20185/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?19/45/20185/contributors\">",
"     Alice M Sheridan, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?19/45/20185/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Feb 28, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The most common cause of death in dialysis patients is cardiovascular disease (CVD). Much of this turns out to be &ldquo;sudden cardiac death&rdquo;-related and not related to classical atherosclerotic lesion-associated pathologies of acute myocardial infarction, and stroke. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/61/26584?source=see_link\">",
"     \"Myocardial dysfunction in end-stage renal disease\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/1/11288?source=see_link\">",
"     \"Evaluation of sudden cardiac arrest and sudden cardiac death in dialysis patients\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    It is increasingly accepted that sudden cardiac death may be due in part to the presence of excess vascular calcification (VC), particularly in the form of extensive coronary artery calcification (CAC), which can be observed even in very young dialysis patients [",
"    <a class=\"abstract\" href=\"UTD.htm?19/45/20185/abstract/1-4\">",
"     1-4",
"    </a>",
"    ]. This may contribute to premature cardiovascular (CVD) disease and the markedly increased mortality observed in the dialysis population [",
"    <a class=\"abstract\" href=\"UTD.htm?19/45/20185/abstract/5-11\">",
"     5-11",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/13/37082?source=see_link\">",
"     \"Patient survival and maintenance dialysis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/44/30410?source=see_link\">",
"     \"Diagnostic and prognostic implications of coronary artery calcification detected by computed tomography\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The presence of CAC in the dialysis population is multi-factorial but appears to correlate, in part, with the quantity of ingested calcium-containing oral phosphate binders (OPB) [",
"    <a class=\"abstract\" href=\"UTD.htm?19/45/20185/abstract/12\">",
"     12",
"    </a>",
"    ]. Such ectopic vascular calcification was commonly noted in patients with renal disease during periods when calcium-containing OPBs were not yet available. This suggests that there are many additional clinical factors also associated with VC and CAC in the dialysis population. Some of these features include increasing use of pharmacologic Vitamin D therapy, increasing age of dialysis cohorts, and dialysis vintage.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Calcium can be deposited into either the medial or intimal layers of the vasculature. Some parts of the vasculature such as smaller muscular arteries (eg, digital) are more susceptible to arteriosclerosis. By contrast atherosclerosis predominates in other territories, (eg, ileo-femoral regions) and in some areas there can be a mix or blend of different lesions.",
"      <br/>",
"      <br/>",
"      The relationship between adverse cardiovascular outcomes and the particular type of calcium deposition is relevant; VC has been shown to be detrimental, but intimal VC confers a worse prognosis than medial VC [",
"      <a class=\"abstract\" href=\"UTD.htm?19/45/20185/abstract/4\">",
"       4",
"      </a>",
"      ]. Intimal calcium deposition, a relatively less common lesion in patients with chronic kidney disease, is principally associated with atherosclerotic plaques. Although such plaques are associated with myocardial infarction and thrombotic events in patients with normal renal function, the association between is less clear in patients with chronic kidney disease.",
"     </li>",
"     <li>",
"      It is clear that many different patient populations that are prone to vascular calcification eg, diabetic patients, older patients, patients with chronic kidney disease, and especially patients on dialysis, calcify faster, and much more extensively, than in any other clinical situation save rare congenital syndromes leading to infantile or juvenile arterial calcification.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In general, it is likely that, among patients with renal disease, both intimal and medial calcification are co-localized in the coronary, aortic, and iliofemoral circulations.",
"   </p>",
"   <p>",
"    This topic review will present a description and pathogenesis of vascular calcification (VC), particularly coronary arterial calcification, in dialysis patients. The clinical implications of VC in renal disease and its potential therapy are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/20/17738?source=see_link\">",
"     \"Vascular calcification in chronic kidney disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     DEFINITION OF VASCULAR CALCIFICATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;All large elastic, medium-sized muscular arteries and arterioles can calcify. By comparison, veins hardly ever undergo these changes, unless injured or arterialized [",
"    <a class=\"abstract\" href=\"UTD.htm?19/45/20185/abstract/13\">",
"     13",
"    </a>",
"    ]; the latter can occur after coronary artery bypass grafting or arteriovenous fistula formation. Patients with pulmonary hypertension may also develop calcification in the pulmonary arterial tree and this may contribute to pulmonary hypertension and right-sided heart muscle disease [",
"    <a class=\"abstract\" href=\"UTD.htm?19/45/20185/abstract/14\">",
"     14",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In the 1970s, calcium in arterial calcifications derived from vessels of uremic subjects was shown to be in the form of hydroxyapatite crystals [",
"    <a class=\"abstract\" href=\"UTD.htm?19/45/20185/abstract/15\">",
"     15",
"    </a>",
"    ]. This form of calcium deposition, which is the same as that found in the skeleton, differs from other types of vessel calcification:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      \"Whitelockite\" is a brushite form of calcium (magnesium) phosphate that is present in calcified stenotic regions of arteriovenous fistulae and in the elastic lamina of the human aorta [",
"      <a class=\"abstract\" href=\"UTD.htm?19/45/20185/abstract/16\">",
"       16",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Calcium oxalate crystals are only found in systemic oxalosis, in which vessel injury, calcification and gangrene are well-described [",
"      <a class=\"abstract\" href=\"UTD.htm?19/45/20185/abstract/17\">",
"       17",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?11/55/12154?source=see_link\">",
"       \"Primary hyperoxaluria\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    One study showed complex and diverse forms of calcium deposits in dialysis patients, including nano-crystalline structures observed by electron microscopy of arterial wall segments [",
"    <a class=\"abstract\" href=\"UTD.htm?19/45/20185/abstract/18\">",
"     18",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    As described above, calcification of arterial walls occurs at two distinct sites, the intimal and medial layers:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Atherosclerotic plaques typically develop associated calcification in the intimal layer as they mature and start to become \"complex.\" This is a hallmark of advancing atherosclerosis, which is seen in muscular arteries such as the aorta and coronaries [",
"      <a class=\"abstract\" href=\"UTD.htm?19/45/20185/abstract/19\">",
"       19",
"      </a>",
"      ]; this process begins in childhood and adolescence. However, this form of calcification may actually stabilize atherosclerotic plaques and reduce the risk of acute plaque rupture [",
"      <a class=\"abstract\" href=\"UTD.htm?19/45/20185/abstract/20\">",
"       20",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Medial calcification is the term given to calcification of the elastic laminae of large and medium-sized arteries (particularly around fractured disorganized elastin fibers). Medial calcification is responsible for the \"pipe-stem\" or \"tram-line\" appearances that were once called M&ouml;nckeberg's medial calcinosis.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Calcium can be deposited into either the medial or intimal layers of the vasculature. The relationship between adverse cardiovascular outcomes and the particular type of calcium deposition is a source of controversy in the nephrology community.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Some investigators contend that calcium deposition in the medial layer, a common finding in dialysis patients, is not clearly associated with adverse cardiovascular outcomes [",
"      <a class=\"abstract\" href=\"UTD.htm?19/45/20185/abstract/21\">",
"       21",
"      </a>",
"      ]; by comparison, others feel that such deposition is associated with stiffening of the vasculature, resulting in significantly adverse cardiovascular outcomes [",
"      <a class=\"abstract\" href=\"UTD.htm?19/45/20185/abstract/22\">",
"       22",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Intimal deposition, a relatively less common lesion in patients with chronic kidney disease, is principally associated with atherosclerotic plaques; in patients with normal renal function, such plaques are clearly associated with myocardial infarction and thrombotic events. While these plaques may calcify, this does not necessarily mean they are more likely to produce ischemic events [",
"      <a class=\"abstract\" href=\"UTD.htm?19/45/20185/abstract/23\">",
"       23",
"      </a>",
"      ]. However, in those with chronic kidney disease, the association between intimal lesions and these adverse outcomes is less clear.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In general, atherosclerosis via intimal lesions results in occlusion, while medial calcification is associated with vascular stiffening. Both intimal and medial vascular calcification are also likely to co-localize in some vessels, such as coronary arteries. Nevertheless, the promoters and risk factors for both types of VC are not necessarily aligned or identical. For example, medial vascular calcification, unlike atherosclerosis, is not principally an inflammatory process and seems exaggerated in diabetes and autonomic neuropathy states [",
"    <a class=\"abstract\" href=\"UTD.htm?19/45/20185/abstract/24\">",
"     24",
"    </a>",
"    ]. It is however associated with apoptosis of medial smooth muscle cells [",
"    <a class=\"abstract\" href=\"UTD.htm?19/45/20185/abstract/25\">",
"     25",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/20/17738?source=see_link\">",
"     \"Vascular calcification in chronic kidney disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     BIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;It was previously thought that &ldquo;passive&rdquo; physicochemical factors alone, such as the calcium-phosphate product and pH (with alkaline pH favoring calcification), regulated the process of vascular calcification [",
"    <a class=\"abstract\" href=\"UTD.htm?19/45/20185/abstract/26\">",
"     26",
"    </a>",
"    ]. However, it has become clear that there is a great similarity between ossification and vascular calcification, with ossification being an elaborately regulated process that involves the synthesis of a matrix that then becomes calcified [",
"    <a class=\"abstract\" href=\"UTD.htm?19/45/20185/abstract/27\">",
"     27",
"    </a>",
"    ]. Osteogenic proteins, such as osteocalcin, osteonectin, alkaline phosphatase, and collagen-I, are increased in the calcified vessel wall and promote differentiation of smooth muscle cells into osteoblasts [",
"    <a class=\"abstract\" href=\"UTD.htm?19/45/20185/abstract/28\">",
"     28",
"    </a>",
"    ]. The expression of these proteins is driven by transcription factors, such as core-binding factor 1alpha (cbfa1) and bone morphogenic protein-2 (",
"    <a class=\"graphic graphic_table graphicRef75006 \" href=\"UTD.htm?37/6/37996\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?19/45/20185/abstract/29-32\">",
"     29-32",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Loss of inhibitors that usually prevent soft tissue calcification seems to play a pivotal role in permitting or accelerating vascular calcification. These inhibitors include matrix Gla-protein, osteopontin, fetuin, pyrophosphate and osteoprotegerin (discussed further below) [",
"    <a class=\"abstract\" href=\"UTD.htm?19/45/20185/abstract/32\">",
"     32",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Clinical and histological descriptions of structures resembling bone and even bone marrow within vessel walls as well as the presence of calcium in the hydroxyapatite form are suggestive that",
"    <strong>",
"     ectopic ossification",
"    </strong>",
"    is the cause of VC. In addition, matrix vesicles are seen in vessel walls in proximity to calcified areas (in bony ossification they serve as the focus for ossification initiation) and immunocytochemistry has demonstrated the presence of characteristic bone-related proteins, such as collagen I and a number of noncollagenous bone matrix proteins.",
"   </p>",
"   <p>",
"    The mechanisms by which medial and intimal calcification occurs may be different:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Medial calcification is believed to be similar to membranous bone formation, a developmental process during which mesenchymal cells are directly transformed to osteoblasts without a cartilage intermediate.",
"     </li>",
"     <li>",
"      By comparison, intimal calcification more closely resembles endochondral bone formation. With this process, mesenchymal cells are first transformed to chondrocytes, which are then ossified.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Given that elements of mineral metabolism (particularly calcium, phosphate, PTH, and others) are altered in renal insufficiency, it is not surprising that these same elements may in part underlie progressive vascular calcification in patients with chronic kidney disease. The following section will provide an overview of the various factors possibly underlying vascular calcification, with an emphasis (when possible) on elements important in the uremic state.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Genetics",
"    </span>",
"    &nbsp;&mdash;&nbsp;Many animal models suggest that genetic factors are important in the tendency to calcify [",
"    <a class=\"abstract\" href=\"UTD.htm?19/45/20185/abstract/33\">",
"     33",
"    </a>",
"    ]. In the mouse, for example, one genetic element that contributes to aortic and myocardial calcification is the Dyscalc locus [",
"    <a class=\"abstract\" href=\"UTD.htm?19/45/20185/abstract/34\">",
"     34",
"    </a>",
"    ]. Additional models of vascular calcification include the MGP-null, apolipoprotein-E-null, b-glucuronidase deficient KLOTHO, carbonic anhydrase II deficient, desmin-null, and osteoprotegerin-null animals [",
"    <a class=\"abstract\" href=\"UTD.htm?19/45/20185/abstract/35\">",
"     35",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    By comparison, there is a paucity of evidence concerning the role of genetic factors in humans, with many studies in patients without renal disease being underpowered [",
"    <a class=\"abstract\" href=\"UTD.htm?19/45/20185/abstract/36-39\">",
"     36-39",
"    </a>",
"    ]. One large investigation concluded that, after adjusting for multiple risk factors, 42 percent of the residual variation in CAC quantity in patients with coronary disease was attributable to genetic factors [",
"    <a class=\"abstract\" href=\"UTD.htm?19/45/20185/abstract/36\">",
"     36",
"    </a>",
"    ]. Similar studies have",
"    <strong>",
"     not",
"    </strong>",
"    been performed in patients with renal dysfunction.",
"   </p>",
"   <p>",
"    In patients without renal failure, mutations in the ecto-nucleotide",
"    <span class=\"nowrap\">",
"     pyrophosphate/phosphodiesterase",
"    </span>",
"    1 enzyme and polymorphisms within well known genes and functionally characterized cellular and extracellular proteins (such as E-selectin, ACE",
"    <span class=\"nowrap\">",
"     I/D",
"    </span>",
"    gene, and TNF genes) have been linked with a genetic susceptibility to VC [",
"    <a class=\"abstract\" href=\"UTD.htm?19/45/20185/abstract/40-46\">",
"     40-46",
"    </a>",
"    ]. Thus far no study has attempted to examine the associations of any of these genetic alterations with vascular calcification in renal failure patients.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Biochemistry",
"    </span>",
"    &nbsp;&mdash;&nbsp;The exact biochemical mechanisms underlying vascular calcification in renal insufficiency are poorly understood. This is largely a result of the difficulties posed in interpreting cross-sectional data because of the large number of confounding factors (",
"    <a class=\"graphic graphic_table graphicRef65338 \" href=\"UTD.htm?36/30/37356\">",
"     table 2",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    The following are some of the biochemical alterations possibly associated with vascular calcification in renal failure:",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     Hyperphosphatemia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hyperphosphatemia may contribute to the phenotype change of vascular smooth muscle cells by upregulating the sodium-dependent cotransporter, Pit1 [",
"    <a class=\"abstract\" href=\"UTD.htm?19/45/20185/abstract/47\">",
"     47",
"    </a>",
"    ]. Increased activity of Pit1 leads to upregulation of many genes associated with matrix mineralization [",
"    <a class=\"abstract\" href=\"UTD.htm?19/45/20185/abstract/48\">",
"     48",
"    </a>",
"    ]. As shown in animal models, preventing hyperphosphatemia can decrease vascular calcification [",
"    <a class=\"abstract\" href=\"UTD.htm?19/45/20185/abstract/49,50\">",
"     49,50",
"    </a>",
"    ]. This has also been shown indirectly in humans. While it is tempting to suggest that there can be no calcification without hyperphosphatemia, we feel this is a simplification which is not completely valid. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/20/17738?source=see_link\">",
"     \"Vascular calcification in chronic kidney disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Hyperparathyroidism",
"    </span>",
"    &nbsp;&mdash;&nbsp;Primary hyperparathyroidism has long been recognized as a risk factor for cardiovascular disease, via an increased incidence of general calcification, hypertension, and left ventricular hypertrophy [",
"    <a class=\"abstract\" href=\"UTD.htm?19/45/20185/abstract/51-53\">",
"     51-53",
"    </a>",
"    ]. Secondary (and tertiary) hyperparathyroidism have also been linked to cardiovascular pathology in many studies of experimental animals [",
"    <a class=\"abstract\" href=\"UTD.htm?19/45/20185/abstract/54\">",
"     54",
"    </a>",
"    ]. However, the relationship of PTH levels per se to clinical cardiovascular disorders in humans remains speculative [",
"    <a class=\"abstract\" href=\"UTD.htm?19/45/20185/abstract/55\">",
"     55",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Vitamin D",
"    </span>",
"    &nbsp;&mdash;&nbsp;Vitamin D therapy, particularly when administered in excess, is a potential vascular toxin, being associated with in vitro phenomena that could predispose to in vivo plaque calcification and atherosclerosis [",
"    <a class=\"abstract\" href=\"UTD.htm?19/45/20185/abstract/56,57\">",
"     56,57",
"    </a>",
"    ]. The ability of vitamin D to calcify the medial layer of arteries (predominantly) has been noted in animals and in humans as reported in most, but not all [",
"    <a class=\"abstract\" href=\"UTD.htm?19/45/20185/abstract/58\">",
"     58",
"    </a>",
"    ], studies [",
"    <a class=\"abstract\" href=\"UTD.htm?19/45/20185/abstract/59-65\">",
"     59-65",
"    </a>",
"    ]. As an example, a post-mortem investigation in children with end-stage renal disease reported an association between vitamin D use and VC, but no correlation with VC was found for calcium and phosphate levels [",
"    <a class=\"abstract\" href=\"UTD.htm?19/45/20185/abstract/64\">",
"     64",
"    </a>",
"    ]. In addition, in a plain X-ray study of VC in hemodialysis patients, an association reportedly existed between levels of vitamin D metabolites and the extent and progression of VC [",
"    <a class=\"abstract\" href=\"UTD.htm?19/45/20185/abstract/59\">",
"     59",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Clinical doses of vitamin D frequently result in hypercalcemia and an elevated calcium-phosphate product. These abnormalities can accelerate extra-osseous calcification. 1,25-dihydroxy vitamin D (1,25(OH)2D3) may also stimulate vascular calcification, as suggested by in vitro studies, via the direct inhibition of the expression of PTH-related peptide (PTHrP), which is an endogenous inhibitor of vascular calcification [",
"    <a class=\"abstract\" href=\"UTD.htm?19/45/20185/abstract/66\">",
"     66",
"    </a>",
"    ]. In addition, 1,25(OH)2D3 enhances alkaline phosphatase activity and osteopontin (a chemoattractant) expression, both of which may promote VC.",
"   </p>",
"   <p>",
"    Untreated vitamin D deficiency also appears to contribute to vascular calcification via a variety of mechanisms. These include lowering parathyroid hormone-related peptide (PTH-rP) levels (which normally inhibit vascular calcification [",
"    <a class=\"abstract\" href=\"UTD.htm?19/45/20185/abstract/66\">",
"     66",
"    </a>",
"    ]), and suppressing Cbfa1 and bone morphogenic proteins (which enhance the transformation of vascular smooth muscle cells into osteoclast [",
"    <a class=\"abstract\" href=\"UTD.htm?19/45/20185/abstract/67\">",
"     67",
"    </a>",
"    ]). Thus, the level of vitamin D that is maintained is critically important, since both an excess and deficiency of vitamin D can contribute to the vascular calcification via different mechanisms. In one study of children without other vascular pathology, vitamin D levels were associated with calcification of coronary arteries and with carotid intima-media thickening, with both low and high 1.25 di-OH vitamin D levels [",
"    <a class=\"abstract\" href=\"UTD.htm?19/45/20185/abstract/25\">",
"     25",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Independent of their effect upon calcium and phosphate levels, limited evidence in animal models suggests that the available vitamin D receptor agonists may differ in their effect upon vascular calcification [",
"    <a class=\"abstract\" href=\"UTD.htm?19/45/20185/abstract/68\">",
"     68",
"    </a>",
"    ]. This has not yet been extensively studied clinically. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/58/32681?source=see_link\">",
"     \"Management of secondary hyperparathyroidism and mineral metabolism abnormalities in adult predialysis patients with chronic kidney disease\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/36/38474?source=see_link\">",
"     \"Management of secondary hyperparathyroidism and mineral metabolism abnormalities in dialysis patients\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Lipids",
"    </span>",
"    &nbsp;&mdash;&nbsp;Lipids and lipid-related factors also contribute to VC. Oxidized lipids can induce inflammation and",
"    <span class=\"nowrap\">",
"     endothelial/vascular",
"    </span>",
"    smooth muscle cell damage as an integral part of atherosclerosis, with calcification being the end-result of an inflammatory process.",
"   </p>",
"   <p>",
"    High density lipoprotein (HDL) regulates the osteoblastic differentiation and calcification of vascular cells, with lower HDL levels associated with increased adverse effects of oxidized-LDL. As a result, increased arterial calcification in patients with a lower HDL level has been reported with and without renal dysfunction [",
"    <a class=\"abstract\" href=\"UTD.htm?19/45/20185/abstract/69-71\">",
"     69-71",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Inflammation",
"    </span>",
"    &nbsp;&mdash;&nbsp;The chronic inflammatory milieu of uremia may contribute to vascular calcification. A large number of proinflammatory or anti-inflammatory substances have been evaluated as possible factors underlying this abnormal milieu. These include osteopontin, osteoprotegerin and fetuin. Osteopontin (a chemoattractant) concentrations in blood and in atherosclerotic plaques are increased in hemodialysis patients compared to age-matched healthy controls, and may correlate with aortic calcification score [",
"    <a class=\"abstract\" href=\"UTD.htm?19/45/20185/abstract/72\">",
"     72",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Inflammatory states and chronic kidney disease are also associated with altered levels of osteoprotegerin and alpha-2-Heremann Schmitt glycoprotein (AHSG, or human fetuin). Both of these factors are considered protective against extraosseous calcification [",
"    <a class=\"abstract\" href=\"UTD.htm?19/45/20185/abstract/73\">",
"     73",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Normal levels of fetuin help clear apoptotic cells, which act as potential niduses for crystal formation in medial arterial calcification, by augmenting phagocytosis [",
"    <a class=\"abstract\" href=\"UTD.htm?19/45/20185/abstract/74\">",
"     74",
"    </a>",
"    ]. In vitro, fetuin appears to inhibit the precipitation of hydroxyapatite from supersaturated solutions of calcium and phosphate via the formation of a fetuin-mineral complex (FMC), which contains calcium phosphate, matrix Gla-protein (MGP), fetuin, and other fetuin-like compounds [",
"    <a class=\"abstract\" href=\"UTD.htm?19/45/20185/abstract/75,76\">",
"     75,76",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Low fetuin levels, which are observed with CKD and other chronic inflammatory states, are associated with increased vascular calcification, cardiovascular mortality, and overall mortality in some studies of dialysis patients [",
"    <a class=\"abstract\" href=\"UTD.htm?19/45/20185/abstract/77-84\">",
"     77-84",
"    </a>",
"    ]. The sera of dialysis patients with low fetuin concentrations also demonstrated impaired capacity to inhibit",
"    <span class=\"nowrap\">",
"     calcium/phosphate",
"    </span>",
"    precipitation [",
"    <a class=\"abstract\" href=\"UTD.htm?19/45/20185/abstract/85\">",
"     85",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Osteoprotegerin competes with the ligand-cell membrane receptor pair, receptor activator of NF-kB ligand (RANKL) and its receptor RANK, that is found on osteoclast precursor cell membranes by acting as a decoy receptor for RANK [",
"    <a class=\"abstract\" href=\"UTD.htm?19/45/20185/abstract/86\">",
"     86",
"    </a>",
"    ]. The interplay between these regulatory factors is implicated in vascular disease, with RANKL and osteoprotegerin promoting and protecting against vascular calcification, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?19/45/20185/abstract/87\">",
"     87",
"    </a>",
"    ]. However, both low and high serum concentration of osteoprotegerin have been reportedly associated with vascular calcification [",
"    <a class=\"abstract\" href=\"UTD.htm?19/45/20185/abstract/82,88,89\">",
"     82,88,89",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Pyrophosphate is a naturally occurring inhibitor of calcification that is reduced in chronic kidney disease and may promote vessel calcification especially among patients on dialysis [",
"    <a class=\"abstract\" href=\"UTD.htm?19/45/20185/abstract/90\">",
"     90",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Although pyrophosphate synthesis can occur spontaneously, tissue pyrophosphate release is regulated by three factors, including the membrane-bound enzyme tissue non-specific alkaline phosphatase (TNAP); the rate-limiting enzyme ecto-nucleotide pyrophosphatase phospho-diesterase-1 (ENPP-1); and the transmembrane transporter ANK, encoded by the 'progressive ankylosis' locus [",
"    <a class=\"abstract\" href=\"UTD.htm?19/45/20185/abstract/90\">",
"     90",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Both genetic ANK and ENPP-1 deficiencies cause dystrophic calcification in mice and loss-of-function mutations of ENPP-1 cause idiopathic infantile arterial calcification (IIAC) leading to severe vascular calcifications in neonates and small children, usually causing early death.",
"   </p>",
"   <p>",
"    The role of inflammation in the medial aortic vascular calcification observed with CKD is uncertain. With this pathology, apoptotic bodies in the elastin-layer of the vessel media act as crystallization niduses in medial calcification [",
"    <a class=\"abstract\" href=\"UTD.htm?19/45/20185/abstract/24\">",
"     24",
"    </a>",
"    ]. This differs from atherosclerosis, which has inflammatory cells and lipid-deposition in the intima. It should be noted that there is controversy regarding this distinction between medial and intimal calcification [",
"    <a class=\"abstract\" href=\"UTD.htm?19/45/20185/abstract/91,92\">",
"     91,92",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Osteogenesis factors",
"    </span>",
"    &nbsp;&mdash;&nbsp;Core-binding factor alpha(1) (Cbfa1) is an essential transcription factor for osteoblastic differentiation and osteogenesis. It is also a key regulatory factor in the vascular calcification observed in dialysis patients, and is upregulated in response to many uremic toxins.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Calcifying vascular cells",
"    </span>",
"    &nbsp;&mdash;&nbsp;An important factor leading to ectopic calcification is calcifying vascular cells (CVCs) [",
"    <a class=\"abstract\" href=\"UTD.htm?19/45/20185/abstract/93\">",
"     93",
"    </a>",
"    ]. The presence of osteocalcin in vessels, which is pathognomonic of osteoblastic terminal differentiation, hints at the existence of such a cell with an osteoblastic phenotype. Primary VSMC cultures from explants of medial tissue from normal and diseased blood vessels have been derived, resulting in cells that adopt a calcifying phenotype [",
"    <a class=\"abstract\" href=\"UTD.htm?19/45/20185/abstract/94\">",
"     94",
"    </a>",
"    ]; this includes the synthesis of a series of bone-regulating proteins, either spontaneously or after manipulation of culture conditions (which include elevation of tissue culture phosphate levels). Induction of heme-oxygenase 1",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    ferritin appears to inhibit the development of CVCs [",
"    <a class=\"abstract\" href=\"UTD.htm?19/45/20185/abstract/95\">",
"     95",
"    </a>",
"    ]. Apoptosis of medial smooth muscle cells may contribute to local calcium deposition [",
"    <a class=\"abstract\" href=\"UTD.htm?19/45/20185/abstract/25\">",
"     25",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Vascular calcification induced by hyperphosphatemia has been hypothesized to be an adaptive transition of the vascular smooth muscle cell from a contractile to an",
"    <span class=\"nowrap\">",
"     osteogenic/chondrogenic",
"    </span>",
"    phenotype, which is characterized by calcifying vesicle formation, downregulation of mineralization inhibitory molecules, and elaboration of a calcification prone matrix [",
"    <a class=\"abstract\" href=\"UTD.htm?19/45/20185/abstract/12\">",
"     12",
"    </a>",
"    ]. Sustained exposure to increased plasma phosphate concentrations may result in increased",
"    <span class=\"nowrap\">",
"     osteogenic/chondrogenic",
"    </span>",
"    gene expression and simultaneous downregulation of smooth muscle (SM) lineage gene expression (SM-actin, SM22) in experimental models. As an example, upregulation of the transcription factor, Runx2, induces expression of major bone matrix components including type I collagen, osteocalcin, and OPN; decreased expression of Runx2 inhibits osteogenic conversion and matrix mineralization [",
"    <a class=\"abstract\" href=\"UTD.htm?19/45/20185/abstract/12\">",
"     12",
"    </a>",
"    ].",
"    <br/>",
"    <br/>",
"    Alkaline phosphatase is required for normal bone formation and may regulate vascular matrix mineralization by inactivating the mineralization inhibitors, pyrophosphate and osteopontin, and liberating free plasma phosphate. The",
"    <span class=\"nowrap\">",
"     osteogenic/chondrogenic",
"    </span>",
"    phenotype change induced by hyperphosphatemia is characterized ultrastructurally by the appearance of matrix vesicles containing apatite and calcifying collagen fibrils on the surface of vascular smooth muscle cells. As in bone, these vesicles most likely act as early nucleation sites for calcification [",
"    <a class=\"abstract\" href=\"UTD.htm?19/45/20185/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In addition, hydroxyapatite nanocrystals shed from vesicles may promote mineralization via direct effects on smooth muscle cell (SMC) phenotype. In support of this concept, synthetic hydroxyapatite nanocrystals and isolated high-P-induced nanocrystals induced",
"    <span class=\"nowrap\">",
"     osteogenic/chondrogenic",
"    </span>",
"    gene expression in VSMCs [",
"    <a class=\"abstract\" href=\"UTD.htm?19/45/20185/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     Other factors",
"    </span>",
"    &nbsp;&mdash;&nbsp;Other potentially relevant contributors to the process of VC appear to exist. Support for this is provided by cases of aggressive systemic calcinosis, calcific uremic arteriolopathy, and arterial calcification being reported in patients after renal transplantation [",
"    <a class=\"abstract\" href=\"UTD.htm?19/45/20185/abstract/96-99\">",
"     96-99",
"    </a>",
"    ]. However, post-transplantation hypercalcemia and hyperparathyroidism (two calcifying promoters on dialysis) more rarely persist in the engrafted patient, with hypophosphatemia (hence normal or often low calcium-phosphate product due to PTH and FGF-23 derived renal phosphate loss) actually being the norm in the immediate post-engraftment period. Similarly, the use of vitamin D and phosphate binders of any sort after renal transplantation is unusual.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Is there a plausible biologic rationale for VC?",
"    </span>",
"    &nbsp;&mdash;&nbsp;Vessel calcification may be a manifestation of a repair response to vessel injury in the presence of calcium-phosphate derangement. This hypothesis is attractive since uremia causes vessel injury, most notably at the endothelial cell level.",
"   </p>",
"   <p>",
"    One theory compares the constant remodeling of the bony skeleton to the stress and strain associated with the cyclical shear-stress in vessel walls. Increases in bone mass on exercise, and its reduction in bed-bound patients or weightless astronauts in response to the presence or absence of stress and strain progresses via an early increase in intracellular calcium mediated by stretch-activated cationic channels (SA-CAT). This leads to changes in cytoskeletal architecture, up-regulation of anabolic bone activity manifested by osteopontin, and increased mineralization (at least in vitro) [",
"    <a class=\"abstract\" href=\"UTD.htm?19/45/20185/abstract/33\">",
"     33",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    As a result, one could speculate that, in response to increased cyclical shear-stress and strain in the vessel wall of large arteries, there would be fragmentation and fracturing of elastin fibers in the tunica media, to which resident calcifying vascular cells would respond by (medial) mineralization [",
"    <a class=\"abstract\" href=\"UTD.htm?19/45/20185/abstract/100,101\">",
"     100,101",
"    </a>",
"    ]. This would be catalyzed by \"uremic factors\" (eg phosphate, dyslipidemia, oxidative stress, lack of inhibitors of calcification) [",
"    <a class=\"abstract\" href=\"UTD.htm?19/45/20185/abstract/102\">",
"     102",
"    </a>",
"    ]. This speculation would fit with clinical observations about the patterns and onset of vascular calcification and functional vessel changes in uremic subjects.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Vascular calcification in patients with chronic kidney disease, noted radiologically for decades, has been of increasing interest within the renal literature. Two distinct, but potentially co-localizing, forms of VC, intimal and medial calcification, have been identified. These are most likely two separate processes:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Medial VC is related to excess calcium and phosphate levels, and damage to elastin, with micro-crystalline matrix vesicles.",
"     </li>",
"     <li>",
"      Intimal VC is observed as a part of advanced atherosclerosis, is inflammatory, and is associated with cholesterol deposition.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These calcification patterns have different implications:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The presence of calcium in the intimal layer is associated with &ldquo;occlusive&rdquo; intimal disease. This can stiffen blood vessels and is associated with marked reduction in endothelial reactivity.",
"     </li>",
"     <li>",
"      The presence of calcium in the vessel media has a direct adverse effect on vascular distensibility leading to increased vessel stiffness.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    There may well be common risk factors to both types of calcification. These include excess calcium and phosphate, and decreased circulating, or tissue-bound, inhibitors of the calcification process. Both appear to progress by a series of elaborate mechanisms similar to bony ossification and may involve genetic susceptibility or gene polymorphisms.",
"   </p>",
"   <p>",
"    A variety of proteins and tissue factors as well as soluble circulating molecules have been implicated in the pathogenesis of VC, although the exact mechanisms remain to be unraveled. Central to this discussion is the remediable factors including vitamin D therapy and the use of calcium containing OPBs in prevention of VC. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/20/17738?source=see_link\">",
"     \"Vascular calcification in chronic kidney disease\"",
"    </a>",
"    .)",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/45/20185/abstract/1\">",
"      Braun J, Oldendorf M, Moshage W, et al. Electron beam computed tomography in the evaluation of cardiac calcification in chronic dialysis patients. Am J Kidney Dis 1996; 27:394.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/45/20185/abstract/2\">",
"      Goodman WG, Goldin J, Kuizon BD, et al. Coronary-artery calcification in young adults with end-stage renal disease who are undergoing dialysis. N Engl J Med 2000; 342:1478.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/45/20185/abstract/3\">",
"      Chertow GM, Burke SK, Raggi P, Treat to Goal Working Group. Sevelamer attenuates the progression of coronary and aortic calcification in hemodialysis patients. Kidney Int 2002; 62:245.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/45/20185/abstract/4\">",
"      London GM, Gu&eacute;rin AP, Marchais SJ, et al. Arterial media calcification in end-stage renal disease: impact on all-cause and cardiovascular mortality. Nephrol Dial Transplant 2003; 18:1731.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/45/20185/abstract/5\">",
"      Block GA, Hulbert-Shearon TE, Levin NW, Port FK. Association of serum phosphorus and calcium x phosphate product with mortality risk in chronic hemodialysis patients: a national study. Am J Kidney Dis 1998; 31:607.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/45/20185/abstract/6\">",
"      Block GA. Prevalence and clinical consequences of elevated Ca x P product in hemodialysis patients. Clin Nephrol 2000; 54:318.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/45/20185/abstract/7\">",
"      Goldsmith D, MacGinley R, Smith A, Covic A. How important and how treatable is vascular stiffness as a cardiovascular risk factor in renal failure? Nephrol Dial Transplant 2002; 17:965.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/45/20185/abstract/8\">",
"      London GM, Marchais SJ, Guerin AP, et al. Arterial structure and function in end-stage renal disease. Nephrol Dial Transplant 2002; 17:1713.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/45/20185/abstract/9\">",
"      Blacher J, Guerin AP, Pannier B, et al. Impact of aortic stiffness on survival in end-stage renal disease. Circulation 1999; 99:2434.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/45/20185/abstract/10\">",
"      Blacher J, Pannier B, Guerin AP, et al. Carotid arterial stiffness as a predictor of cardiovascular and all-cause mortality in end-stage renal disease. Hypertension 1998; 32:570.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/45/20185/abstract/11\">",
"      Blacher J, Guerin AP, Pannier B, et al. Arterial calcifications, arterial stiffness, and cardiovascular risk in end-stage renal disease. Hypertension 2001; 38:938.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/45/20185/abstract/12\">",
"      Shanahan CM, Crouthamel MH, Kapustin A, Giachelli CM. Arterial calcification in chronic kidney disease: key roles for calcium and phosphate. Circ Res 2011; 109:697.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/45/20185/abstract/13\">",
"      Leu HJ, Brunner U. [Calcified and ossified phlebosclerosis]. Vasa 1992; 21:11.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/45/20185/abstract/14\">",
"      Smith JC, Stanton LW, Kramer NC, Parrish AE. Nodular pulmonary calcification in renal failure. Report of a case. Am Rev Respir Dis 1969; 100:723.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/45/20185/abstract/15\">",
"      Contiguglia SR, Alfrey AC, Miller NL, et al. Nature of soft tissue calcification in uremia. Kidney Int 1973; 4:229.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/45/20185/abstract/16\">",
"      Verberckmoes SC, Persy V, Behets GJ, et al. Uremia-related vascular calcification: more than apatite deposition. Kidney Int 2007; 71:298.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/45/20185/abstract/17\">",
"      Galimberti RL, Parra IH, Imperiali N, et al. Fatal cutaneous necrosis in a hemodialyzed patient with oxalosis. Int J Dermatol 1999; 38:918.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/45/20185/abstract/18\">",
"      Schlieper G, Aretz A, Verberckmoes SC, et al. Ultrastructural analysis of vascular calcifications in uremia. J Am Soc Nephrol 2010; 21:689.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/45/20185/abstract/19\">",
"      Stary HC. Lipid and macrophage accumulations in arteries of children and the development of atherosclerosis. Am J Clin Nutr 2000; 72:1297S.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/45/20185/abstract/20\">",
"      Mohler ER 3rd. Vascular calcification: good, bad or ugly? Vasc Med 2002; 7:161.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/45/20185/abstract/21\">",
"      McCullough PA, Sandberg KR, Dumler F, Yanez JE. Determinants of coronary vascular calcification in patients with chronic kidney disease and end-stage renal disease: a systematic review. J Nephrol 2004; 17:205.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/45/20185/abstract/22\">",
"      Chertow GM. Slowing the progression of vascular calcification in hemodialysis. J Am Soc Nephrol 2003; 14:S310.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/45/20185/abstract/23\">",
"      Hunt JL, Fairman R, Mitchell ME, et al. Bone formation in carotid plaques: a clinicopathological study. Stroke 2002; 33:1214.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/45/20185/abstract/24\">",
"      Proudfoot D, Shanahan CM. Biology of calcification in vascular cells: intima versus media. Herz 2001; 26:245.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/45/20185/abstract/25\">",
"      Shroff RC, McNair R, Skepper JN, et al. Chronic mineral dysregulation promotes vascular smooth muscle cell adaptation and extracellular matrix calcification. J Am Soc Nephrol 2010; 21:103.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/45/20185/abstract/26\">",
"      Mulligan, RM. Metastatic calcification. Arch Pathol 1946; 42:177.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/45/20185/abstract/27\">",
"      Virchow, R. Kalk metastasen. Virchows Arch f path Anat 1855; 8:103.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/45/20185/abstract/28\">",
"      Shantouf R, Kovesdy CP, Kim Y, et al. Association of serum alkaline phosphatase with coronary artery calcification in maintenance hemodialysis patients. Clin J Am Soc Nephrol 2009; 4:1106.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/45/20185/abstract/29\">",
"      Ahmed S, O'Neill KD, Hood AF, et al. Calciphylaxis is associated with hyperphosphatemia and increased osteopontin expression by vascular smooth muscle cells. Am J Kidney Dis 2001; 37:1267.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/45/20185/abstract/30\">",
"      Moe SM, O'Neill KD, Duan D, et al. Medial artery calcification in ESRD patients is associated with deposition of bone matrix proteins. Kidney Int 2002; 61:638.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/45/20185/abstract/31\">",
"      Cozzolino M, Gallieni M, Brancaccio D. Vascular calcification in uremic conditions: new insights into pathogenesis. Semin Nephrol 2006; 26:33.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/45/20185/abstract/32\">",
"      Fukagawa M, Kazama JJ. The making of a bone in blood vessels: from the soft shell to the hard bone. Kidney Int 2007; 72:533.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/45/20185/abstract/33\">",
"      Davies MR, Hruska KA. Pathophysiological mechanisms of vascular calcification in end-stage renal disease. Kidney Int 2001; 60:472.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/45/20185/abstract/34\">",
"      Colinayo VV, Qiao JH, Demant P, et al. Genetic characterization of the Dyscalc locus. Mamm Genome 2002; 13:283.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/45/20185/abstract/35\">",
"      Massy ZA, Ivanovski O, Nguyen-Khoa T, et al. Uremia accelerates both atherosclerosis and arterial calcification in apolipoprotein E knockout mice. J Am Soc Nephrol 2005; 16:109.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/45/20185/abstract/36\">",
"      Peyser PA, Bielak LF, Chu JS, et al. Heritability of coronary artery calcium quantity measured by electron beam computed tomography in asymptomatic adults. Circulation 2002; 106:304.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/45/20185/abstract/37\">",
"      Narayan KM, Pettitt DJ, Hanson RL, et al. Familial aggregation of medial arterial calcification in Pima Indians with and without diabetes. Diabetes Care 1996; 19:968.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/45/20185/abstract/38\">",
"      Wagenknecht LE, Bowden DW, Carr JJ, et al. Familial aggregation of coronary artery calcium in families with type 2 diabetes. Diabetes 2001; 50:861.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/45/20185/abstract/39\">",
"      Nitschke Y, Baujat G, Botschen U, et al. Generalized arterial calcification of infancy and pseudoxanthoma elasticum can be caused by mutations in either ENPP1 or ABCC6. Am J Hum Genet 2012; 90:25.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/45/20185/abstract/40\">",
"      Schiffmann JH, Wessel A, Br&uuml;ck W, Speer CP. [Idiopathic infantile arterial calcinosis. A rare cardiovascular disease of uncertain etiology--case report and review of the literature]. Monatsschr Kinderheilkd 1992; 140:27.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/45/20185/abstract/41\">",
"      Rutsch F, Ruf N, Vaingankar S, et al. Mutations in ENPP1 are associated with 'idiopathic' infantile arterial calcification. Nat Genet 2003; 34:379.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/45/20185/abstract/42\">",
"      Ellsworth DL, Bielak LF, Turner ST, et al. Gender- and age-dependent relationships between the E-selectin S128R polymorphism and coronary artery calcification. J Mol Med (Berl) 2001; 79:390.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/45/20185/abstract/43\">",
"      Herrmann SM, Whatling C, Brand E, et al. Polymorphisms of the human matrix gla protein (MGP) gene, vascular calcification, and myocardial infarction. Arterioscler Thromb Vasc Biol 2000; 20:2386.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/45/20185/abstract/44\">",
"      Keso T, Perola M, Laippala P, et al. Polymorphisms within the tumor necrosis factor locus and prevalence of coronary artery disease in middle-aged men. Atherosclerosis 2001; 154:691.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/45/20185/abstract/45\">",
"      Pfohl M, Athanasiadis A, Koch M, et al. Insertion/deletion polymorphism of the angiotensin I-converting enzyme gene is associated with coronary artery plaque calcification as assessed by intravascular ultrasound. J Am Coll Cardiol 1998; 31:987.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/45/20185/abstract/46\">",
"      Rutsch F, Nitschke Y, Terkeltaub R. Genetics in arterial calcification: pieces of a puzzle and cogs in a wheel. Circ Res 2011; 109:578.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/45/20185/abstract/47\">",
"      Huybers S, Bindels RJ. Vascular calcification in chronic kidney disease: new developments in drug therapy. Kidney Int 2007; 72:663.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/45/20185/abstract/48\">",
"      Jono S, McKee MD, Murry CE, et al. Phosphate regulation of vascular smooth muscle cell calcification. Circ Res 2000; 87:E10.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/45/20185/abstract/49\">",
"      Mathew S, Lund RJ, Strebeck F, et al. Reversal of the adynamic bone disorder and decreased vascular calcification in chronic kidney disease by sevelamer carbonate therapy. J Am Soc Nephrol 2007; 18:122.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/45/20185/abstract/50\">",
"      Stubbs JR, Liu S, Tang W, et al. Role of hyperphosphatemia and 1,25-dihydroxyvitamin D in vascular calcification and mortality in fibroblastic growth factor 23 null mice. J Am Soc Nephrol 2007; 18:2116.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/45/20185/abstract/51\">",
"      Slatopolsky E, Martin K, Hruska K. Parathyroid hormone metabolism and its potential as a uremic toxin. Am J Physiol 1980; 239:F1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/45/20185/abstract/52\">",
"      Garcia de la Torre N, Wass JA, Turner HE. Parathyroid adenomas and cardiovascular risk. Endocr Relat Cancer 2003; 10:309.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/45/20185/abstract/53\">",
"      Vestergaard P, Mollerup CL, Fr&oslash;kjaer VG, et al. Cardiovascular events before and after surgery for primary hyperparathyroidism. World J Surg 2003; 27:216.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/45/20185/abstract/54\">",
"      Neves KR, Graciolli FG, dos Reis LM, et al. Vascular calcification: contribution of parathyroid hormone in renal failure. Kidney Int 2007; 71:1262.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/45/20185/abstract/55\">",
"      Covic A, Kothawala P, Bernal M, et al. Systematic review of the evidence underlying the association between mineral metabolism disturbances and risk of all-cause mortality, cardiovascular mortality and cardiovascular events in chronic kidney disease. Nephrol Dial Transplant 2009; 24:1506.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/45/20185/abstract/56\">",
"      Tukaj C, Kubasik-Juraniec J, Kraszpulski M. Morphological changes of aortal smooth muscle cells exposed to calcitriol in culture. Med Sci Monit 2000; 6:668.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/45/20185/abstract/57\">",
"      Shioi A, Mori K, Jono S, et al. Mechanism of atherosclerotic calcification. Z Kardiol 2000; 89 Suppl 2:75.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/45/20185/abstract/58\">",
"      Braam LA, Hoeks AP, Brouns F, et al. Beneficial effects of vitamins D and K on the elastic properties of the vessel wall in postmenopausal women: a follow-up study. Thromb Haemost 2004; 91:373.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/45/20185/abstract/59\">",
"      Goldsmith DJ, Covic A, Sambrook PA, Ackrill P. Vascular calcification in long-term haemodialysis patients in a single unit: a retrospective analysis. Nephron 1997; 77:37.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/45/20185/abstract/60\">",
"      Duguid, JB. Vitamin D sclerosis in the rat's aorta. J Path 1933; 33:697.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/45/20185/abstract/61\">",
"      EISENSTEIN R, ZERUOLIS L. VITAMIN D-INDUCED AORTIC CALCIFICATION. Arch Pathol 1964; 77:27.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/45/20185/abstract/62\">",
"      Mallick NP, Berlyne GM. Arterial calcification after vitamin-D therapy in hyperphosphatemic renal failure. Lancet 1968; 2:1316.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/45/20185/abstract/63\">",
"      Irnell L. Metastatic calcification of soft tissue on overdosage of vitamin D. Acta Med Scand 1969; 185:147.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/45/20185/abstract/64\">",
"      Milliner DS, Zinsmeister AR, Lieberman E, Landing B. Soft tissue calcification in pediatric patients with end-stage renal disease. Kidney Int 1990; 38:931.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/45/20185/abstract/65\">",
"      Lopez I, Mendoza FJ, Aguilera-Tejero E, et al. The effect of calcitriol, paricalcitol, and a calcimimetic on extraosseous calcifications in uremic rats. Kidney Int 2008; 73:300.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/45/20185/abstract/66\">",
"      Jono S, Nishizawa Y, Shioi A, Morii H. 1,25-Dihydroxyvitamin D3 increases in vitro vascular calcification by modulating secretion of endogenous parathyroid hormone-related peptide. Circulation 1998; 98:1302.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/45/20185/abstract/67\">",
"      Drissi H, Pouliot A, Koolloos C, et al. 1,25-(OH)2-vitamin D3 suppresses the bone-related Runx2/Cbfa1 gene promoter. Exp Cell Res 2002; 274:323.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/45/20185/abstract/68\">",
"      Mizobuchi M, Finch JL, Martin DR, Slatopolsky E. Differential effects of vitamin D receptor activators on vascular calcification in uremic rats. Kidney Int 2007; 72:709.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/45/20185/abstract/69\">",
"      Tamashiro M, Iseki K, Sunagawa O, et al. Significant association between the progression of coronary artery calcification and dyslipidemia in patients on chronic hemodialysis. Am J Kidney Dis 2001; 38:64.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/45/20185/abstract/70\">",
"      Achenbach S, Ropers D, Pohle K, et al. Influence of lipid-lowering therapy on the progression of coronary artery calcification: a prospective evaluation. Circulation 2002; 106:1077.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/45/20185/abstract/71\">",
"      Parhami F, Basseri B, Hwang J, et al. High-density lipoprotein regulates calcification of vascular cells. Circ Res 2002; 91:570.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/45/20185/abstract/72\">",
"      Nitta K, Ishizuka T, Horita S, et al. Soluble osteopontin and vascular calcification in hemodialysis patients. Nephron 2001; 89:455.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/45/20185/abstract/73\">",
"      Westenfeld R, Sch&auml;fer C, Kr&uuml;ger T, et al. Fetuin-A protects against atherosclerotic calcification in CKD. J Am Soc Nephrol 2009; 20:1264.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/45/20185/abstract/74\">",
"      Jersmann HP, Dransfield I, Hart SP. Fetuin/alpha2-HS glycoprotein enhances phagocytosis of apoptotic cells and macropinocytosis by human macrophages. Clin Sci (Lond) 2003; 105:273.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/45/20185/abstract/75\">",
"      Price PA, Lim JE. The inhibition of calcium phosphate precipitation by fetuin is accompanied by the formation of a fetuin-mineral complex. J Biol Chem 2003; 278:22144.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/45/20185/abstract/76\">",
"      Price PA, Nguyen TM, Williamson MK. Biochemical characterization of the serum fetuin-mineral complex. J Biol Chem 2003; 278:22153.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/45/20185/abstract/77\">",
"      Stenvinkel P, Wang K, Qureshi AR, et al. Low fetuin-A levels are associated with cardiovascular death: Impact of variations in the gene encoding fetuin. Kidney Int 2005; 67:2383.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/45/20185/abstract/78\">",
"      Ketteler M, Wanner C, Metzger T, et al. Deficiencies of calcium-regulatory proteins in dialysis patients: a novel concept of cardiovascular calcification in uremia. Kidney Int Suppl 2003; :S84.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/45/20185/abstract/79\">",
"      Oh J, Wunsch R, Turzer M, et al. Advanced coronary and carotid arteriopathy in young adults with childhood-onset chronic renal failure. Circulation 2002; 106:100.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/45/20185/abstract/80\">",
"      Stomp&oacute;r T, Pasowicz M, Sulowicz W, et al. An association between coronary artery calcification score, lipid profile, and selected markers of chronic inflammation in ESRD patients treated with peritoneal dialysis. Am J Kidney Dis 2003; 41:203.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/45/20185/abstract/81\">",
"      Ketteler M, Bongartz P, Westenfeld R, et al. Association of low fetuin-A (AHSG) concentrations in serum with cardiovascular mortality in patients on dialysis: a cross-sectional study. Lancet 2003; 361:827.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/45/20185/abstract/82\">",
"      Barreto DV, Barreto FC, Carvalho AB, et al. Coronary calcification in hemodialysis patients: the contribution of traditional and uremia-related risk factors. Kidney Int 2005; 67:1576.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/45/20185/abstract/83\">",
"      Coen G, Manni M, Agnoli A, et al. Cardiac calcifications: Fetuin-A and other risk factors in hemodialysis patients. ASAIO J 2006; 52:150.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/45/20185/abstract/84\">",
"      Hermans MM, Brandenburg V, Ketteler M, et al. Association of serum fetuin-A levels with mortality in dialysis patients. Kidney Int 2007; 72:202.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/45/20185/abstract/85\">",
"      Ketteler M, Vermeer C, Wanner C, et al. Novel insights into uremic vascular calcification: role of matrix Gla protein and alpha-2-Heremans Schmid glycoprotein/fetuin. Blood Purif 2002; 20:473.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/45/20185/abstract/86\">",
"      Zannettino AC, Holding CA, Diamond P, et al. Osteoprotegerin (OPG) is localized to the Weibel-Palade bodies of human vascular endothelial cells and is physically associated with von Willebrand factor. J Cell Physiol 2005; 204:714.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/45/20185/abstract/87\">",
"      Collin-Osdoby P. Regulation of vascular calcification by osteoclast regulatory factors RANKL and osteoprotegerin. Circ Res 2004; 95:1046.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/45/20185/abstract/88\">",
"      Stenvinkel P, Ketteler M, Johnson RJ, et al. IL-10, IL-6, and TNF-alpha: central factors in the altered cytokine network of uremia--the good, the bad, and the ugly. Kidney Int 2005; 67:1216.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/45/20185/abstract/89\">",
"      Moe SM, Reslerova M, Ketteler M, et al. Role of calcification inhibitors in the pathogenesis of vascular calcification in chronic kidney disease (CKD). Kidney Int 2005; 67:2295.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/45/20185/abstract/90\">",
"      O'Neill WC, Sigrist MK, McIntyre CW. Plasma pyrophosphate and vascular calcification in chronic kidney disease. Nephrol Dial Transplant 2010; 25:187.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/45/20185/abstract/91\">",
"      Amann K. Media calcification and intima calcification are distinct entities in chronic kidney disease. Clin J Am Soc Nephrol 2008; 3:1599.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/45/20185/abstract/92\">",
"      McCullough PA, Chinnaiyan KM, Agrawal V, et al. Amplification of atherosclerotic calcification and M&ouml;nckeberg's sclerosis: a spectrum of the same disease process. Adv Chronic Kidney Dis 2008; 15:396.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/45/20185/abstract/93\">",
"      Mizobuchi M, Towler D, Slatopolsky E. Vascular calcification: the killer of patients with chronic kidney disease. J Am Soc Nephrol 2009; 20:1453.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/45/20185/abstract/94\">",
"      Demer LL, Tintut Y, Parhami F. Novel mechanisms in accelerated vascular calcification in renal disease patients. Curr Opin Nephrol Hypertens 2002; 11:437.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/45/20185/abstract/95\">",
"      Zarjou A, Jeney V, Arosio P, et al. Ferritin prevents calcification and osteoblastic differentiation of vascular smooth muscle cells. J Am Soc Nephrol 2009; 20:1254.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/45/20185/abstract/96\">",
"      Giacobetti R, Feldman SA, Ivanovich P, et al. Sudden fatal pulmonary calcification following renal transplantation. Nephron 1977; 19:295.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/45/20185/abstract/97\">",
"      Wenzel-Seifert K, Harwig S, Keller F. Fulminant calcinosis in two patients after kidney transplantation. Am J Nephrol 1991; 11:497.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/45/20185/abstract/98\">",
"      Canavese C, Cesarani F, Stratta C, et al. [Vascular calcification after kidney transplantation. Preliminary results]. Minerva Urol Nefrol 1999; 51:11.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/45/20185/abstract/99\">",
"      Canavese C, Cesarani F, Stratta C, et al. Dramatic worsening of vascular calcifications after kidney transplantation in spite of early parathyroidectomy. Clin Nephrol 2000; 54:487.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/45/20185/abstract/100\">",
"      Atkinson J. [Aging of arterial extracellular matrix elastin: etiology and consequences]. Pathol Biol (Paris) 1998; 46:555.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/45/20185/abstract/101\">",
"      Atkinson J. Arterial calcification. Mechanisms, consequences and animal models. Pathol Biol (Paris) 1999; 47:677.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/45/20185/abstract/102\">",
"      Moe SM, Duan D, Doehle BP, et al. Uremia induces the osteoblast differentiation factor Cbfa1 in human blood vessels. Kidney Int 2003; 63:1003.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 7220 Version 5.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0503-1.234.2.38-35693F307E-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f19_45_20185=[""].join("\n");
var outline_f19_45_20185=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H15\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      DEFINITION OF VASCULAR CALCIFICATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      BIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Genetics",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Biochemistry",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - Hyperphosphatemia",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Hyperparathyroidism",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Vitamin D",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Lipids",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Inflammation",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Osteogenesis factors",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Calcifying vascular cells",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - Other factors",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Is there a plausible biologic rationale for VC?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"NEPH/7220\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"NEPH/7220|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?37/6/37996\" title=\"table 1\">",
"      Main bone morphogenic",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?36/30/37356\" title=\"table 2\">",
"      Confounding factors",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/44/30410?source=related_link\">",
"      Diagnostic and prognostic implications of coronary artery calcification detected by computed tomography",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/1/11288?source=related_link\">",
"      Evaluation of sudden cardiac arrest and sudden cardiac death in dialysis patients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/58/32681?source=related_link\">",
"      Management of secondary hyperparathyroidism and mineral metabolism abnormalities in adult predialysis patients with chronic kidney disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/36/38474?source=related_link\">",
"      Management of secondary hyperparathyroidism and mineral metabolism abnormalities in dialysis patients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/61/26584?source=related_link\">",
"      Myocardial dysfunction in end-stage renal disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/13/37082?source=related_link\">",
"      Patient survival and maintenance dialysis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/55/12154?source=related_link\">",
"      Primary hyperoxaluria",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/20/17738?source=related_link\">",
"      Vascular calcification in chronic kidney disease",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f19_45_20186="Melanocytic lesions";
var content_f19_45_20186=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F53263%7EDERM%2F78335%7EDERM%2F56257&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F53263%7EDERM%2F78335%7EDERM%2F56257&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 532px\">",
"   <div class=\"ttl\">",
"    Dermoscopic structures seen in melanocytic lesions",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 512px; height: 398px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Dermoscopic structures seen in melanocytic lesions.",
"    <br>",
"     (A) Pigment network.",
"     <br>",
"      (B) Negative network.",
"      <div class=\"footnotes\">",
"      </div>",
"      <div class=\"reference\">",
"       Reproduced with permission from: Drs. Ashfaq Marghoob and Natalia Jaimes.",
"      </div>",
"     </br>",
"    </br>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 568px\">",
"   <div class=\"ttl\">",
"    Dermoscopic structures seen in melanocytic lesions",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 548px; height: 413px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    (A) Aggregated globules (solid square) and pigment network (solid arrow) in a melanocytic nevus.",
"    <br>",
"     (B) Homogeneous blue pigmentation seen in a blue nevus.",
"     <br>",
"      (C, D) Streaks: Pseudopods in a Spitz nevus (C) and radial streaming in a melanoma (D).",
"      <div class=\"footnotes\">",
"      </div>",
"      <div class=\"reference\">",
"       Reproduced with permission from: Drs. Ashfaq Marghoob and Natalia Jaimes.",
"      </div>",
"     </br>",
"    </br>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 602px\">",
"   <div class=\"ttl\">",
"    Dermoscopic structures of melanocytic lesions seen on volar and facial skin",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 582px; height: 233px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    (A) Parallel pattern, typically seen in melanocytic lesions on palms and soles (volar surfaces).",
"    <br>",
"     (B) Pseudonetwork pattern seen in pigmented facial lesions.",
"     <div class=\"footnotes\">",
"     </div>",
"     <div class=\"reference\">",
"      Reproduced with permission from: Drs. Ashfaq Marghoob and Natalia Jaimes.",
"     </div>",
"    </br>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f19_45_20186=[""].join("\n");
var outline_f19_45_20186=null;
var title_f19_45_20187="Egg content of vaccines";
var content_f19_45_20187=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ALLRG%2F51011&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ALLRG%2F51011&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Egg content of vaccines (subject to change, check package inserts)",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tr>",
"      <td class=\"subtitle1\">",
"       Vaccine",
"      </td>",
"      <td class=\"subtitle1\">",
"       Grown in",
"      </td>",
"      <td class=\"subtitle1\">",
"       Egg protein content",
"      </td>",
"      <td class=\"subtitle1\">",
"       Approach in egg-allergic patient",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Measles and mumps",
"      </td>",
"      <td>",
"       Chick embryo fibroblast cell cultures",
"      </td>",
"      <td>",
"       Picograms to nanograms",
"      </td>",
"      <td>",
"       Administer in usual manner",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Purified chick embryo rabies",
"      </td>",
"      <td>",
"       Chick embryo fibroblast cell cultures",
"      </td>",
"      <td>",
"       Picograms to nanograms",
"      </td>",
"      <td>",
"       Administer in usual manner",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Influenza (killed injected and live attenuated nasal)",
"      </td>",
"      <td>",
"       Chick extra-embryonic allantoic fluid",
"      </td>",
"      <td>",
"       Micrograms",
"      </td>",
"      <td>",
"       **",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Yellow fever",
"      </td>",
"      <td>",
"       Chick embryos",
"      </td>",
"      <td>",
"       Micrograms",
"      </td>",
"      <td>",
"       Skin test with vaccine prior to administration",
"      </td>",
"     </tr>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     ** Discussed in UpToDate topic \"Influenza vaccination in individuals with egg allergy\"",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f19_45_20187=[""].join("\n");
var outline_f19_45_20187=null;
var title_f19_45_20188="Clinical features of RPC";
var content_f19_45_20188=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=RHEUM%2F76071&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=RHEUM%2F76071&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Frequency of clinical manifestations in 645 patients with relapsing polychondritis",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        &nbsp;",
"       </td>",
"       <td class=\"subtitle1\">",
"        Onset of disease",
"       </td>",
"       <td class=\"subtitle1\">",
"        Course of disease",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        External ear",
"       </td>",
"       <td>",
"        42.9",
"       </td>",
"       <td>",
"        82.9",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        Internal ear (total)",
"       </td>",
"       <td class=\"sublist_other_start\">",
"        11.7",
"       </td>",
"       <td class=\"sublist_other_start\">",
"        37.7",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Auditory",
"       </td>",
"       <td class=\"sublist_other\">",
"        &nbsp;",
"       </td>",
"       <td class=\"sublist_other\">",
"        32.7",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Vestibular",
"       </td>",
"       <td class=\"sublist_other\">",
"        &nbsp;",
"       </td>",
"       <td class=\"sublist_other\">",
"        17.4",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Eye",
"       </td>",
"       <td>",
"        22.2",
"       </td>",
"       <td>",
"        54",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Nasal cartilage",
"       </td>",
"       <td>",
"        27",
"       </td>",
"       <td>",
"        61.4",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Laryngotracheobronchial",
"       </td>",
"       <td>",
"        21.5",
"       </td>",
"       <td>",
"        48.3",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        Joint (total)",
"       </td>",
"       <td class=\"sublist_other_start\">",
"        38.5",
"       </td>",
"       <td class=\"sublist_other_start\">",
"        70.4",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Peripheral",
"       </td>",
"       <td class=\"sublist_other\">",
"        &nbsp;",
"       </td>",
"       <td class=\"sublist_other\">",
"        65.8",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Thoracic cage",
"       </td>",
"       <td class=\"sublist_other\">",
"        &nbsp;",
"       </td>",
"       <td class=\"sublist_other\">",
"        25.2",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        Valvular heart disease",
"       </td>",
"       <td class=\"sublist_other_start\">",
"        &nbsp;",
"       </td>",
"       <td class=\"sublist_other_start\">",
"        10.3",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Aneurysmal formation",
"       </td>",
"       <td class=\"sublist_other\">",
"        &nbsp;",
"       </td>",
"       <td class=\"sublist_other\">",
"        5.1",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Systemic vasculitis",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        14.4",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Skin lesions",
"       </td>",
"       <td>",
"        16.4",
"       </td>",
"       <td>",
"        24.4",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f19_45_20188=[""].join("\n");
var outline_f19_45_20188=null;
var title_f19_45_20189="Acquired PRCA diff diagnosis";
var content_f19_45_20189=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=HEME%2F78795&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=HEME%2F78795&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Differential diagnosis of acquired pure red cell aplasia in children",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\" class=\"container\">",
"     <tbody>",
"      <tr>",
"       <td class=\"container\">",
"        <table cellspacing=\"0\">",
"         <tbody>",
"          <tr>",
"           <td class=\"subtitle1_single\">",
"            Acquired",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"subtitle2_single\">",
"            Primary",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Autoimmune",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist2_start\">",
"            Idiopathic*",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist2\">",
"            Transient erythroblastopenia of childhood (TEC)",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"subtitle1_single\">",
"            Secondary",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"subtitle2_single\">",
"            Thymoma and malignancy",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Thymoma",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Lymphoid malignancies",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Paraneoplastic syndrome with solid tumors",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"subtitle2_single\">",
"            Collagen vascular disorders",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Systemic lupus erythematosus (SLE)",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Juvenile idiopathic arthritis (JIA)",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Rheumatoid arthritis",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"subtitle2_single\">",
"            Infections*",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Parvovirus*",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Hepatitis A, B, C",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Epstein-Barr virus (EBV)",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Human immunodeficiency virus (HIV)",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Human herpesvirus 6 (HHV6)",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Echovirus 11",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"subtitle1_single\">",
"            Autoantibodies",
"           </td>",
"          </tr>",
"         </tbody>",
"        </table>",
"       </td>",
"       <td class=\"container\">",
"        <table cellspacing=\"0\">",
"         <tbody>",
"          <tr>",
"           <td class=\"subtitle1_single\">",
"            Pregnancy",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"subtitle1_single\">",
"            Malnutrition/protein deficiency",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"subtitle1_single\">",
"            Drugs",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"subtitle2_single\">",
"            Drugs probably associated",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Phenytoin",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Azathioprine",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Isoniazid",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Chlorpropamide",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Valproic acid",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Chloramphenicol and thiamphenicol",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Sulfonamides",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Procainamide",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"subtitle2_single\">",
"            Drugs possibly associated",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Allopurinol",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Carbamazepine",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Chloroquine",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Dapsone",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Fenoprofen",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Penicillamine",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Gold",
"           </td>",
"          </tr>",
"         </tbody>",
"        </table>",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * Common causes of acquired&nbsp;pure red cell aplasia&nbsp;in the pediatric population.",
"    </div>",
"    <div class=\"reference\">",
"     Data from:",
"     <br>",
"      <ol>",
"       <li>",
"        Alter BP, Young NS. The Bone Marrow Failure Syndromes. In: Nathan and Oski's Hematology of Infancy and Childhood, Nathan DG, Orkin SH (Eds), W.B. Saunders Company, 1998, p.237.",
"       </li>",
"       <li>",
"        Thompson DF, Gales MA, Pharmacotherapy 1996; 16:1002.",
"       </li>",
"       <li>",
"        Lin YW, Okazaki S, Hamahata K, et al, Am J Hematol 1999; 61:209.",
"       </li>",
"      </ol>",
"     </br>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f19_45_20189=[""].join("\n");
var outline_f19_45_20189=null;
var title_f19_45_20190="Steroid side effects time dose";
var content_f19_45_20190=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=RHEUM%2F53432&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=RHEUM%2F53432&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Time course of steroid side effects",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 349px; height: 235px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Survival curves demonstrating the time to development of the first serious adverse event (ie, the probability of remaining free of an adverse event) in patients with rheumatoid arthritis treated with no or different doses of prednisone. There is a clear dose- dependence of side effects: odds ratio 4.5 for 5 to 10 mg/day, and 32.3 for 10 to 15 mg/day.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from Saag, KG, Koehnke, R, Caldwell, JR, et al. Am J Med 1994; 96:115.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f19_45_20190=[""].join("\n");
var outline_f19_45_20190=null;
var title_f19_45_20191="Approach otorrhea";
var content_f19_45_20191=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F78623&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F78623&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 606px\">",
"   <div class=\"ttl\">",
"    Approach to otorrhea in children",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 586px; height: 484px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     AOM: acute otitis media; CSF: cerebrospinal fluid.",
"     <br>",
"      * Meningitis, brain abscess, epidural abscess, subdural empyema, lateral or cavernous sinus thrombosis, or carotid artery thrombosis.",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f19_45_20191=[""].join("\n");
var outline_f19_45_20191=null;
